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This study was conducted in the Tygerberg district, Cape Town, in the Western 
Cape, South Africa 
 
Background 
The evaluation of early tuberculosis (TB) treatment response is based on month 2 
sputum culture status. This method of evaluation has a number of limitations: the test 
requires relatively advanced laboratory infrastructure and procedures, it takes several 
weeks to obtain results and is a relatively a poor marker at predicting treatment 
response. The discovery of potential host markers which reflect the efficacy of early 
treatment would be of great importance for clinical management of individual 
patients. The treatment failure would be detectable earlier than at week 8 of 
treatment. The duration of clinical trials of new anti-tuberculosis drugs may also be 
substantially reduced by such markers if these would be measurable earlier than at 
week 8 of therapy.  
 
Objectives 
1) To evaluate diluted, 7-day whole blood cultures stimulated with live 
Mycobacterium tuberculosis (M.tb) for the presence of host markers of early TB 
treatment response 
2) To evaluate an overnight, undiluted, M.tb antigen stimulated whole blood culture 
Quantiferon Gold In Tube (QFT-GIT) supernatants for host markers of early TB 
treatment response 
The study designs were as follows: 
In study one, baseline samples and samples from week 1, week 2 and week 4 of 
treatment from 30 cured TB patients were selected from a larger biomarker study, in 
which whole blood was stimulated with live M.tb or left unstimulated. Fifty seven host 
markers were measured in supernatants by multiplex cytokine arrays.  
 
In study two, baseline samples and samples from week 2 and week 8 of treatment 
from 19 cured TB patients were randomly selected from the placebo group in a 
micronutrient supplement study. QFT-GIT supernatants from these participants were 





All of the participants in both studies were Human Immunodeficiency Virus (HIV) 
negative. 
Changes in marker expression over time and between fast and slow responders to 
treatment were evaluated. Comparability between the two culture methods was 
assessed for markers that were evaluated in both studies. 
Results 
In study one, the majority of host markers showed significant changes over time in 
the unstimulated supernatants. Only GRO and IL-1beta changed significantly in an 
antigen-specific manner (background levels subtracted). No significant changes were 
observed between fast and slow responders. 
In study two, the majority of host markers showed significant changes over time in 
the unstimulated supernatants whereas only MDC and IL-4 changed during the 
observation period in antigen stimulated levels. Significant differences were observed 
between fast and slow responders at pre-treatment for IL-13 Ag-Nil   and IL-1betaAg-Nil . 
Conclusion 
This study revealed, antigen-specific responses showed only limited potential for 
early TB treatment response monitoring, but may have potential in differentiating 
between treatment outcomes. Future investigations may have to include later time 
points during treatment as these were not included in the present assessment. The 
QFT-GIT samples do not appear to be equivalent to live M.tb stimulated 7-day whole 

















Die studie is uitgevoer in die Tygerbergdistrik, Kaapstad, Wes-Kaap, Suid-Afrika. 
 
Agtergrond 
Die evaluering van die respons op vroeë tuberkulose (TB) behandeling word 
gebaseer op die status van maand 2 sputum kulture. Hierdie evalueringsmetode het 
‘n paar beperkinge: die toets benodig relatief gevorderde laboratorium infrastruktuur 
en prosedures, die toetsuitslae is eers na ‘n paar weke beskikbaar en dit is n 
relatiewe swak merker om repons op behandeling te voorspel. Die ontdekking van 
potensiële selfmerkers wat die doeltreffendheid van vroeë behandeling weerspieël 
sal van groot belang wees vir die kliniese bestuur van individuele pasiënte. 
Mislukking van die behandeling sal sodoende voor week 8 van behandeling 
waargeneem kan word. Die tydsduur van kliniese proewe van nuwe anti-tuberkulose 
medikasie mag ook baie verkort word met sulke merkers as dit voor week 8 van 
behandeling gemeet kan word. 
 
Doelwitte 
1) Om verdunde, 7-dae oue volbloedkulture, met lewende Mikobakterium 
tuberkulosis (M.tb) gestimuleer, te evalueer vir die teenwoordigheid van 
vroeë TB behandeling respons selfmerkers. 
2) Om die supernatant van oornag, onverdunde, M.tb antigeen 
gestimuleerde volbloedkulture Quantiferon Gold In Tube (QFT-GIT) vir vroeë 
behandeling respons selfmerkers te evalueer. 
Die studie-ontwerpe was soos volg: 
Met studie een is basislynmonsters en monsters verkry na week 1, week 2 en week 4 
van behandeling van 30 geneesde TB-pasiënte geselekteer uit ‘n groter 
biomerkerstudie waarin die volbloed met lewende M.tb gestimuleer is of 
ongestimuleer gelaat is. Sewe-en-vyftig selfmerkers is in die supernatante gemeet 
deur middel van multipleks sitokine arrays. 
 
Met studie twee is basislynmonsters en monsters verkry na week 2 en week 8 van 





mikrovoedingstowwe-aanvullingstudie geselekteer. Vlakke van 57 selfmerkers is in 
die QFT-GIT supernatante van hierdie deelnemers, deur middel van die multipleks 
sitokine arrays, bepaal.  Al die deelnemers van beide studies was HIV negatief. 
Veranderinge in merker-uitdrukking oor tyd, asook tussen vinnige en stadige respons 
tot behandeling, is ge-evalueer. Die vergelykbaarheid van die twee kultuurmetodes is 
geassesseer ten opsigte van die ge-evalueerde merkers in albei studies.  
Resultate 
Met studie een het die meerderheid van die selfmerkers in die ongestimuleerde 
supernatante kenmerkende verandering oor tyd gewys. Slegs GRO en IL-1beta het 
aansienlik verander in die antigeenspesifieke wyse (agtergrond vlakke afgetrek). 
Geen kenmerkende veranderinge was waargeneem tussen die vinnige en stadige 
respons pasiënte nie. 
Met studie twee het die meerderheid van die selfmerkers aansienlike veranderinge 
oor tyd in die ongestimuleerde supernatante gewys, in vergelyking waar net die MDC 
en IL-4 veranderinge gedurende die observasie periode in antigeen gestimuleerde 
vlakke getoon het. Kenmerkende verskille is tussen die vinnige en stadige respons 
pasiënte in voorbehandeling vir IL-13 Ag-Nil   en IL-1betaAg-Nil waargeneem. 
Gevolgtrekking 
Die studie bewys dat antigeenspesifieke response slegs beperkte potensiaal vir 
vroeë TB behandeling respons monitering het, maar mag die potensiaall vir 
onderskeidende behandeling uitkomste hê. Toekomstige ondersoeke sal dalk latere 
tydpunte gedurende die behandeling moet insluit aangesien dit nie in hierdie 
evaluasie ingesluit is nie. Die QFT-IT monsters verskyn nie as gelykwaardig met die 
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1.1   Global Tuberculosis Burden  
Tuberculosis (TB) is one of the most common infectious diseases in humans, has 
been described as the “white plague1 and is caused by the pathogen Mycobacterium 
tuberculosis (M.tb). 
The World Health Organisation (WHO) has estimated that one third of the world’s 
population is infected asymptomatically with M.tb, of whom 5 to 10% have a life time 
risk of developing clinical disease.2 In 2010 the WHO, reported 8.8 million incident TB 
cases and 1.4 million TB deaths. Currently, South East Asia and Africa rank the 
highest in the absolute numbers of cases per year with South Africa in third position 
following India and China.3 
Despite the fact that TB itself is a threat to the world population, co-infection with HIV 
has further increased the risk of TB disease progression and deaths. It was 
estimated that 1.2 million incident cases of TB were infected with HIV and 350 000 
deaths were reported due to HIV/TB co-infection. In the African region it was 
estimated that 82% of the TB cases were co-infected with HIV in 2010.4 HIV infected 
individuals have a 10% annual risk of developing TB whereas HIV negative 
individuals have a 10% life time risk.5  
Despite the availability of anti-tuberculosis chemotherapy, some regions battle with 
an increase in multidrug resistant tuberculosis (MDR-TB) and extensively drug 
resistant tuberculosis (XDR-TB) strains of M.tb.  Incorrect treatment regimens and 
non-adherence to anti-tuberculosis therapy have facilitated the spread of disease. 
The XDR-TB epidemic in Kwazulu–Natal was an example of how dangerous and 
rapid a disease can spread without the correct monitoring and treatment.6  
The use of optimally working vaccines is the most cost efficient measure for the 
control of any disease. The only recommended vaccine for TB is Bacilli Calmette 
Guerin (BCG), it was developed in 1921 and found to be useful and cost effective 
against miliary TB in neonates.7 In adult pulmonary TB, the BCG vaccine has proven 





The spread of drug resistant strains, HIV co-infection, the absence of short and 
effective treatment regimens and the absence of effective new vaccines pose serious 



































Figure 1.1 Estimates of the prevalence of HIV in new TB cases by country in 2010. Dark 
coloured areas represent regions with a high rate of HIV/TB co-infection, while grey and 
lighter blue areas reflect areas with lower HIV/TB co-infection. Source: WHO REPORT 2011: 












Figure 1.2 Estimates of rates of TB incidence, by country in 2010. Dark green areas 
represent regions with high TB incident cases, while the grey and lighter green reflects areas 





1.2 M. tb: Causative agent of human TB 
M. tuberculosis, which causes TB is a rod shaped, slow-growing, acid-fast, aerobic, 
non-motile bacterium with a replication time of 15-20 hours.9 The cell wall structure of 
mycobacteria is unique compared to fast-growing bacteria. The complex 
mycobacterial cell wall is composed of unusual amounts of lipid moieties i.e. 
peptidoglycolipids (mycosides), cord factors and sulpholipids which provide 
hydrophobic characteristics, acid fast properties and enable intracellular survival of 
the bacterium within the macrophage.10,11 
1.3 Tuberculosis – Clinical Forms 
M.tb has the ability to cause infection anywhere in the body but it mainly resides in 
the oxygen rich lungs.12 The route of infection occurs via inhalation of aerolised 
droplets which are either coughed up or sneezed out by a person with active TB. The 
droplet nuclei are particles of 1-5µm in diameter and can remain suspended in the air 
for a number of minutes or hours. The likelihood of M.tb infection is increased by the 
number of bacilli inhaled, frequency of exposure and the general immune status of 
the potential host.13,14 
The host response plays a major role in determining the clinical manifestations and 
outcomes of persons who are exposed to the M.tb pathogen. 
There are a number of possible outcomes that can occur when a person first 
encounters M.tb. First, some hosts have the ability to destroy the bacillus through the 
activity of innate responses, in particular through the antimicrobial activity of alveolar 
macrophages, which results in the host remaining uninfected. These hosts do not 
develop immunological sensitization to the bacterium (T or B cell responses). 
Second, the bacilli may escape eradication and a population of bacilli may remain in 
a state of dormancy within the host. This is termed as latent infection, which is 
manifested by a positive tuberculin skin test (TST) or positive interferon gamma 
release assays (IGRAs). Finally, if this state of latency is compromised active 
disease occurs, accompanied by common clinical symptoms, i.e. chronic cough, 
fever, night sweats and weight loss.15 
Only 10% of people who are exposed to the bacillus will progress to active disease 
within 2-5 years of becoming infected.16 The remainder (90%) of people who are 
infected but not diseased are not able to spread the bacilli. Immunosuppressive 





involve HIV17, therapies such as tumour necrosis factor (TNF) neutralization 
therapy18, diabetes and immune senescence (old age).19 
1.4 Immune responses to M.tb Infections 
A foreign molecule that enters into the host has the ability to initiate a series of 
defence mechanisms in the body.12 The immune system has two branches namely, 
the innate and the adaptive immune system. M.tb has the ability to stimulate both of 
these branches. As M.tb has adapted well to survive inside some immune cells, like 
macrophages, a major component of the protective response against this pathogen is 
the cell mediated immune response. For the destruction of M.tb, lymphocytes need to 
be activated, which in turn activate macrophages to improve their ability to kill 
intracellular pathogens. Ninety percent of exposed individuals do not develop active 
TB disease and this demonstrates that the interplay between innate and adaptive 
immune responses is generally effective in preventing progression to active TB 
disease.  
1.4.1 Innate Immunity 
Following inhalation, the bacillus travels down the trachea of the new host and 
reaches the small airways and lung parenchyma. The bacillus encounters alveolar 
macrophages (AMOs) and dendritic cells (DCs), which form the first line of defence 
within the lung.12 Many receptors such as the complement and mannose receptors 
aid the entry of the bacillus into the host phagocytic cells.12 These receptors can 
directly or indirectly attach to the surfaces of the sugar residues within the pathogen 
cell wall20and result in the expression of pro-inflammatory signals.21 Toll-like receptors 
(TLRs) are pattern recognition receptors that are able to identify pathogen molecules, 
including mycobacterium components. TLRs activate the intracellular signalling 
cascades that promote inflammation but can also activate signals that reduce the 
innate immune response.22 TLRs also play a role in the differentiation of monocytes 
into macrophages.23 
After bacillary uptake, the bacteria enter a phagosome which traffics within the AMO 
and fuses with lysosomes to form a phago-lysosome which results in a reduction of 
the intra-phagosomal pH and the production of nitrogen and oxygen radicals.24This 
may lead to the destruction of the bacteria with no persistence of infection. When the 
host fails to kill the bacteria but manages to inhibit growth, a state of ‘dormancy’ or 
quiescent infection may be established. The infected macrophage release 
inflammatory mediators, which induce the extravasations of phagocytic cells 





weeks after infection, a cell mediated T cell response becomes detectable which 
results in a further release of inflammatory molecules. This releases cytokines and 
chemokines that regulate the migration of leukocytes to the site of infection and 
further activate other macrophages to initiate the formation of a granuloma.25 
1.4.2 Granuloma Composition and Function 
The granuloma is the hallmark of the host immune response against mycobacteria 
and it is believed that these cellular structures play an important role to contain the 
bacillus. The production of TNF and Interferon (IFN)-γ from the infected macrophage 
stimulate the involvement of neutrophils; NK cells, CD4, CD8 T lymphocytes, DCs 
and B lymphocytes. Each of these cells produces their own cytokines that increase 
cellular recruitment and remodelling of the infection site.26,27 
The function of the granuloma is to contain and prevent the spread of the infectious 
bacilli at the primary site of the infection by starving the bacilli from oxygen and 
nutrients which are essential for their survival. A microenvironment for immune cross-
talk between host cells leading to macrophage and lymphocyte activation, cytokine 
production and the killing of the bacteria by CD8 T lymphocytes is also a function of 
the granuloma.25 This limits inflammation to the infection site and decreases 
multiplication of the bacilli. 
The granuloma structure comprises of a necrotic centre, which results in the death of 
the majority of bacteria. This area is surrounded by a layer of macrophages, 
epitheloid cells and multinucleated Langerhans cells and lymphocytes.28 
The surviving bacilli remain in a quiescent or latent state and can become reactivated 
due to immunosupression, either due to HIV infection or due to a poor health status 
of the infected person. These are the main causes for the unchecked replication of 
bacilli enclosed in the granuloma, ultimately resulting in active tuberculosis.29,27 
The innate immune system therefore has important functions in initiating the immune 
response against mycobacteria but also provides some of the final effector functions 
of the adaptive immune response. 
1.4.3 Adaptive Immunity 
(i) Cell mediated immunity to M.tb 
CD4 T lymphocytes play an essential role in the protective immune response to 
M.tb.30,31 The primary residence of the bacteria is within the phagosome of the 





Histocompatibility Complex (MHC) class II pathway. The importance of CD4 T cells in 
the protective immunity to M.tb has been demonstrated in several studies using mice 
models and humans. Studies using mice that were deficient in CD4 T cells were 
characterised by an impaired ability to control the infection due to the steady increase 
of mycobacterial growth in all organs which resulted in death.32 In humans, the 
protective role of CD4 T cells in TB is striking because HIV-mediated decrease of 
CD4 T cell numbers results in progressive primary infection, reactivation of latent 
infection and exacerbate TB disease.33–36 
CD4 T cells comprise of subclasses, among which T helper (TH1) and TH2 cells 
produce cytokines which are important in the outcome of the immune response. Due 
to the release of IL-12 from the activated macrophages, CD4 T cells can develop into 
TH1 cells and release cytokines such as IFN-γ, TNF-α and Interleukin 2 (IL-2). These 
cytokines have the ability to activate macrophages to kill or inhibit the growth of 
mycobacteria.17 The release of IL-4 leads to the development of TH2 cells, which are 
able to produce cytokines such as IL-13, IL-5 and IL-10 and support B cell growth 
and differentiation37 but suppress the TH1 immune response.38 
CD4 T cells can also develop into TH17 cells due to the release of IL-23, IL-6, and IL-
21 to produce IL-17 and IL-22 and stimulate defensin production and recruit 
monocytes to the inflammation site.39 
(ii) CD8 T Cells 
M.tb antigens are processed and presented to CD8 T cells, also called cytotoxic T 
lymphocytes (CTL), via MHC class I molecules. It is believed that CD8 T cells are 
less important than CD4 T cells in the protection against TB, but a murine study 
showed that a defective function of CD8 T cells due to a loss of function of β2 
microglobulin, resulted in increased susceptibility to M.tb.40 CD8 T cells are activated 
due the mediation of M.tb which enhances perforin, granulysin, IFN-γ and Fas-L 
synthesis, which kill infected cells, and hence intracellular bacteria through different 
mechanisms.41 Granulysin alters the integrity of the bacterial cell and together with 
perforin, reduces the viability of M.tb.42 The ability for CD8 T cells to release IFN-γ 
and the ability to use different mechanisms to kill bacilli makes this cell type an 
effective killer during M.tb infection.43 A subset of CD8T cells expressed the 
chemokine RANTES together with perforin and granulysin. RANTES attracted the 







1.4.4 Cytokines and M.tb Infection 
Cytokine profiles may serve as indicators of the immune activation status. Different 
cytokines possess biological overlapping functions which give them the ability to 
control and regulate the production of other cytokines. The analysis of the function of 
a complete set of cytokines expressed within a micro-environment (ie. the site of 
inflammation) is often of more value when looking at a single cytokine at a time.12 
(i)  IL-12 
IL-12 is produced by activated macrophages or dendritic cells upon phagocytosis of 
M.tb, triggering a TH1 response and IFN-γ production by CD4 and CD8 T cells.45,46 
IL- 12 is a critical cytokine in controlling M.tb infection. In one study it was shown that 
mice that had a deficiency in their IL-12p40 gene were highly susceptible to 
intravenous infection with M.tb and were unable to control bacterial growth within the 
lung47and IL-12 that was administered exogenous to BALB/c mice showed to prolong 
their survival.48 Humans with mutations in IL-12p40 or the IL-12 receptor genes 
showed a reduction in IFN-γ and were more susceptible to mycobacterium 
infections.49 In a previous study it was shown that the administration of IL-12 DNA 
could significantly reduce bacterial numbers in mice suffering from chronic M.tb.50 
This suggests that the induction of this cytokine could play a major role in the design 
of TB vaccines. 
(ii) IFN-γ 
IFN-γ plays a central role in controlling M.tb infection. It is produced by CD4, CD8 T 
cells and NK cells during M.tb infection. Individuals who have defective genes for 
IFN-γ or IFN-γ receptors are prone to serious mycobacterial infections.51 In a 
previous study, patients presented with disseminated infection with Mycobacterium 
bovis BCG or environmental mycobacterium, due to a IFN-γ receptor deficiency 
which resulted in some cases of death and survivors were required to continue anti-
mycobacterial treatment.52 
Mechanisms have been developed by M.tb to limit the activation of macrophages by 
IFN-γ.53,54,55,56 This gives an indication that that the amount of IFN-γ produced by T 
cells may be less predicative of outcome than the ability of the cells to respond to this 
cytokine. In one murine study it was shown that the IFN-γ levels produced in 
response to a potential vaccine do not always correlate with how effective the 
vaccine is during M.tb infection.57 Therefore IFN-γ is important in the development of 
an immune response that lengthens the life span of an infected animal, but this 






TNF is a cytokine which is produced by macrophages in response to a pathogen. 
TNF plays a role in recruiting inflammatory cells to the site of an infection which 
results in the containment of bacilli within a macrophage but it is not required for the 
initiation of an antigen-specific T cell response.25,58,59 In previous studies involving 
mice and zebra fish embryos, the absence of TNF caused granuloma formation to be 
halted and variable increases in bacterial growth. These observations indicate that 
TNF plays a direct role in controlling mycobacteria in granuloma macrophages and 
this may  indicate that TNF functions indirectly in decreasing mycobacterial growth by 
modulating the maintenance of the granuloma.60–62 The over production of TNF is 
associated with autoimmune diseases such as Crohn disease and psoriatic arthritis. 
Neutralizing TNF is used for the treatment of these diseases but promotes the 
possible reactivation of latent tuberculosis in individuals that are M.tb infected.63  
 (iv)  IL-4 
IL-4 is one of the cytokines that promotes the immune system to induce the TH2 
response. This cytokine is considered to be detrimental to the host protective 
mechanisms against TB. High levels of IL-4 have been shown to impair BCG 
vaccine-induced protection in the developing world where IL-4 elevation in people 
with helminth infection exists.64 Increased levels of IL-4 have been noted to correlate 
with serum IgE concentration and with the extent of cavitations in CXR in patients 
with pulmonary TB.65,66  In  a study using IL-4 delta 2 (IL-4δ2), a splice variant and 
an inhibitor of IL-4, it was found that both were increased in active TB and only IL-
4δ2 was elevated in individuals with latent infection.67,68 
1.6 Diagnosis of Tuberculosis 
There is no technique available for the diagnosis of TB that is sensitive, specific, cost 
effective, rapid and freely available at high incidence areas. Therefore the 
development of a secure and quick test is important in order to interrupt the 
transmission of TB.  Microbiological tests such as microscopy and culture are used to 
diagnosis TB. Currently, immunological techniques are available which show an 
improvement in the detection process. M.tb infection without disease relies on 
immunological tests.  
(i) TST 
In 1891 Robert Koch isolated a compound called tuberculin which was prepared from 
a liquid culture of tubercle bacilli in order to use as a therapeutic vaccine against 





of purified protein derivative (PPD) which is used to diagnosis M.tb infection in the 
TST.70 The TST is an in vivo test in which PPD is injected intra-dermally in the 
forearm and read within 48-72 hours. A positive reaction shows indurations and 
swelling, which is caused by delayed type hypersensitivity (DTH) reaction.71 Even 
though the TST has a high sensitivity for infection with M.tb its specificity is poor as 
many antigens present in the PPD are also present in the BCG and in other Non-
tuberculous mycobacteria (NTM).72 Further the TST cannot differentiate latent TB 
from active TB, which is a problem in high incidence areas.73 
(ii) Radiology 
Radiographic screening or Chest X ray (CXR) allows for the visualisation of cavities 
and infiltrates in the upper lungs. This method is used to screen and monitor the 
progression of pulmonary TB (PTB).73 CXR have been discouraged for the diagnosis 
of PTB as it is restricted in diagnosing smear negative TB among TB suspect 
patients.29 The sensitivity and specificity of the CXR to detect culture-positive TB 
cases depends on the presentation of the disease and its intensity76. This is 
influenced by a number of factors which include; HIV status, delay in diagnosis, sex 
of the patient and misdiagnosis is common due to the lank of specialist radiology 
support.73 Radiology remains only a supportive diagnostic tool and is subject to 
confirmation by microbiologic culture. 
(iii) Microscopy and Culture 
Microscopic visualization of M.tb using the Ziehl-Neelsen (ZN) staining method to 
detect acid-fast bacilli (AFB) is the most widely used method, inexpensive and results 
can be delivered within hours.74 AFB testing by microscopy requires 5x104 bacilli/ml 
concentrations in sputum samples due to this, many immuno-suppressed individuals 
are missed as they present with low bacterial counts.75 Diagnosis in children is 
difficult as they do not always produce collectable sputum.76 Some modifications prior 
to staining, including cyto-centrifugation or overnight sedimentation, have been found 
to increase the concentration of AFB in the smear and results in higher sensitivity.77 
 
In order to confirm the presence of M.tb, culture is regarded as the gold standard to 
confirm a case of TB. The sputum has to be cultured in solid or liquid media, a 
process which also involves decontamination and speciation (confirmatory 
biochemical analysis or Polymerase chain reaction (PCR).78 The Mycobacterial 
growth indicator tube (MGIT) is the most commonly used culture system, as it is run 
in an automated system and positive results can be obtained within two weeks 





culture systems.79 The advantage of using sputum culture is that its more sensitive 
than AFB testing but culture does have many disadvantages such as  it takes up to 
two weeks or more to confirm results, with delays in the confirmation process, it’s a 
costly process, requires a complex laboratory system with a bio safety level 3 
laboratory and the possibly of contamination, which would produce false positive 
results79.  
(iv) Nucleic-Acid Amplification Tests (NAATs) 
NAATs involve a two-step PCR method which involves the amplification of a specific 
sequence of M.tb DNA.78 Tests include “in-house” which are developed in non-
commercial laboratories and commercial kits. These commercial kits use different 
methods to amplify the specific nucleic regions in M.tb.76 The Roche Amplicor M.tb 
PCR which amplifies the region of 16s ribosomal RNA gene of M.tb.78 The 
advantages of using these tests is that results can be obtained within 3-6 hours and 
can distinguish M.tb from NTM which is useful in populations with a high incidence of 
NTMs.74 Although the NAATs have shown in several studies to have a high specificity 
and low sensitivity, these tests cannot replace culture and microscopy but should be 
used in accordance with these tests together with the clinical data to diagnose TB.78 
NAATs are not useful in monitoring the progress of TB treatment as these tests 
detect non-viable bacteria and produce false positive results.74 
(v) Gene Xpert MTB/ RIF  
The Gene Xpert MTB/RIF is an automated ex vivo gene amplification molecular test 
which has the ability to diagnose TB and detect any resistance to the drug RIF which 
is one of main drugs used in the treatment of TB and it also serves as an indicator for 
multidrug resistance.98 Test results can be obtained within two hours with high levels 
of sensitivity and specificity. However its use is limited in detecting latent M.tb.108 
(vi)  Interferon gamma release assays (IGRAs) 
Other assays rely on proliferation of lymphocytes after exposure to M.tb antigen. To 
be able to detect M.tb infection without detecting NTM’s or M.bovis BCG, antigens 
that are specific for M.tb have to be used. The region of difference (RD1) codes for 
antigenic proteins which are restricted to the M.tb complex, including the 6-kDa early 
secreted antigen target-6 (ESAT-6) and culture filtrate protein 10 (CFP-10).80 Those 
antigens have been used in two commercial interferon gamma release assays 
(IGRA), the Quantiferon-TB Gold (QFT) (together with TB 7.7) and the T-SPOT.TB 





cells of sensitized individuals who have re-encountered M.tb antigens will produce 
IFN-γ.  
The T-SPOT.TB test is an in vitro test in which isolated mononuclear cells are 
stimulated with ESAT-6 and CFP-10. Effector cells, T cells which have been recently 
been exposed to the TB antigen, will be able to produce IFN-γ84 while the memory T 
cells are less likely to produce IFN-γ due to the short incubation time. 
The Quantiferon-TB GOLD test is an Enzyme Linked Immunosorbent Assay (ELISA) 
based test whereby IFN-γ in culture supernatant is measured by ELISA.82, 83 
The WHO has issued a set of guidelines for the use of IGRAs in low and middle 
income countries, it stated that IGRAs and TST could not truly predict the likelihood 
of an infected individual to progress to active TB and due to this, IGRAs and TST 
should not be used to diagnose active TB. Due to the cost and technical implications, 
IGRAs cannot replace the TST test.1 
IGRAs and TST tests are used to detect latent TB, they are “indirect tests” which do 
not detect the viable M.tb bacilli but an immune response will indicate a past or 
present exposure to M.tb.83 
The IGRA is a short time assay and only effector T cells are detected, the T cells in 
the TST test have more time to expand to memory T cells.85,86 Overall it is believed 
that that the IGRAs were not more sensitive when compared to the  TST for the 
diagnosis of TB.84  
1.7 TB treatment 
In the 19th century, TB symptoms were not recognized to belonging to a single 
diseases entity, let alone being caused by an infectious disease.87 In 1854 Herman 
Brehemar, who suffered from TB, went to the Himalayas and when he was 
subsequently cured this was ascribed to the climate. He opened the first TB 
treatment sanatorium where TB patients were treated by enforcing good nutrition, 
bed rest and fresh air.88 These sanatoria were introduced throughout Europe. After 
1919 more drastic methods were applied such as induction of artificial pneumothorax 
and surgery but these methods remained controversial and had potentially serious 
side-effects.87 In 1946 streptomycin was the first antibiotic discovered to be effective 
against TB.89 Other drugs such as para-salicyclic acid (PAS) and isoniazid (INH) 
were also introduced, but the bacteria developed resistance within a short period of 





associated with the development of drug resistance. Today INH is still used as a first 
line drug together with Rifampicin (RMP), Pyrazinamide (PZA) and Ethambutol 
(EMB) in the two month intensive phase of treatment, followed by four months of INH 
and RMP.91   
1.8 Directly Observed Treatment (DOT) and Directly Observed 
Treatment- Short Course (DOTS) 
A study directed by Wallence Fox of the British Medical Research Council in Madra, 
India, was one of the first studies to implement directly observed treatment (DOT). 
Home and sanatorium based drug therapy were compared and it was concluded that 
the sanatorium based patients, despite good nursing, rest and constant monitoring, 
did not fare better than those that were treated at home. This meant that the great 
expense of hospitalisation could be avoided and treatment would be more cost 
effective and more appropriate for resource poor settings.92 This study resulted in the 
implementation of DOTS strategy  by the World Health Organisation (WHO), which 
was launched in the mid 1990’s which consists of a five-point policy, which the third 
policy states that standard short course chemotherapy should be administrated to all 
individuals that are smear-positive under the correct and controlled case 
management conditions.93 DOT seeks to improve the adherence of people to TB 
treatment through health workers, family or community members who directly 
observe patients taking their anti-tuberculosis treatment.94 The advantage with this 
system is that people are closely monitored, but many patients stop taking their 
medication as soon as they start to feel better. The DOT strategy prevented 
prolonged illness and decreased the continued transmission of TB in many 
communities.95 
Despite the implementation of DOTS, the relapse and failure rates are still too high. 
Patients receiving the standard six month regime who have drug susceptible 
organisms still have an estimated failure rate of 1-4% and a relapse rate of up to 
7%.96 
1.9 The potential of Biomarkers to evaluate anti-TB Therapies 
The tools used to evaluate TB treatment, especially in clinical trials, are expensive 
and time-consuming. The clinical indicator of treatment success is the sum of 
treatment failures which is defined as the presence of continued or a recurrence of 
positive cultures during the course of anti-tuberculosis treatment and a relapse is 
defined as an individual who has become culture negative at the end of anti-





clinical evidence that is consistent with active TB112 at the end of a 2 year period after 
treatment. A phase III trial of new TB treatment with relapse as an end-point would 
require the participation of over 2500 participants and a follow up period of four 
years.97 In a study done by Visser, et al it identified a number of factors which could 
delay the sputum culture conversion at month 2 in patients with positive smear 
tuberculosis; these included a shorter Time to detection (TTD) at baseline, tobacco 
smoking, the appearance of cavities  in the upper lungs and the W-Beijing 
genotype.113 
 
It has been suggested that if predictive biomarkers existed for TB treatment response 
it would help in clinical practice and shorten clinical trials.98   
Several biomarker discovery approaches are being developed for TB. For instance, 
specific mRNA molecules are being used to monitor mycobacterial viability. Antigen 
85B RNA has shown to clear more rapidly than viable sputum colony counts during 
therapy and may be a good marker for early treatment effect.99,100 There has been 
some interest in looking at pathogen markers in urine as such samples can be easily 
collected and relatively safe and easy to process. The presence of small fragments of 
M.tb IS6110 DNA in the urine of 79% (34/43) of TB patients but not in healthy 
controls and may have treatment response applications but this needs further 
investigation.101 
 
Other approaches have looked at non-specific immune activation markers such as 
CRP102, neopterin103 and pro-calcitonin104 to follow TB and other bacterial diseases in 
humans. In principle, following any of these markers would be useful for assessing 
responses to anti-TB therapy as host immunity is essential for controlling TB and for 
suppressing reactivation.105 
 
More prospective studies need to be conducted in order to validate the potential 
candidate biomarkers. Candidate biomarkers may have to be discovered in smaller 
study groups due to cost-implications of the discovery techniques like next 
generation sequencing, metabolomics or proteomics.106 It is essential that these 
studies are well designed with clear clinical phenotypes. Clinical characteristics that 
are important include extent of disease at baseline, time of culture conversion and 
time to positivity (TTP), sputum culture status after two months of therapy, and final 
treatment outcome, including cured, treatment failure and relapse.107 Studies should 
also be conducted in different settings, including different geographical locations to 





pathogens or environmental factors like concurrent parasitic infections or other 







1.10 Study Hypotheses and Objectives 
1.10.1 Hypotheses 
Stimulation of blood samples from people with active M.tb infection with M.tb 
antigens will result in the expression of biomarkers, which will correlate with early TB 
treatment response. 
1.10.2 Objectives 
 To evaluate diluted, 7-day whole blood cultures stimulated with live M.tb for 
the presence of host markers of early treatment response 
 





















 Material and Methods 
2.1 Study Setting 
These studies were conducted at the Immunology Research Laboratory, Division of 
Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences of 
the University of Stellenbosch. The participants all enrolled from the Western Cape 
Province, South Africa. One study (Micronutrient Study) recruited from the Delft clinic 
and the second study (Surrogate Marker Study) from five primary health care TB 
clinics near the Tygerberg Academic Hospital (Ravensmead, Uitsig, Adriaanse, 
Elsiesriver and Leonsdale). The clinics in these communities apply the DOTS 
strategy for treating tuberculosis. The Ravensmead/Uitsig community has an 
extremely high prevalence of TB infection as the prevalence has been reported as in 
this area as 1000 per 100 000.109 
2.2 Ethical Issues 
For the Surrogate Marker studies (Chapter 3) ethics was obtained from the 
Committee for Human Research of the University of Stellenbosch (ref number 99-
039). Ethical approval for the Micronutrient study (Chapter 4) was obtained from the 
University of Cape Town Research and Ethics Committee (Project ethics number 
137/2003). Written informed consent was obtained from all participants. All 
participants were counselled before and after their HIV test was performed. 
2.3 Study participants 
2.3.1 A prospective evaluation of surrogate markers for treatment 
response and outcome in adult patients with pulmonary tuberculosis 
(Surrogate Marker Study) - Chapter 3 
The participants for this study were recruited from the five primary health care TB 
clinics mentioned in 2.1 between 15 May 1999 and 15 July 2002. Details of this study 
have been published by Hesseling et al., 2010.110 This study’s main focus was to 
assess immunological and micro-bacterial markers for TB recurrence after initial 
successful TB treatment amongst South African participants. Principal investigators 
for this study included Prof. N. Beyers, P. Van Helden and G. Walzl from 
Stellenbosch University. The study was part of the GlaxoSmith Kline sponsored 





The inclusion and exclusion criteria for participants were: 
Inclusion criteria:  
 Two positive sputum smears using the ZN staining 
 Age between 20-65 years  
 Willingness to undergo HIV testing   
 Willingness to give informed consent for participation in the study 
Exclusion criteria:  
 Refusal to participate, including for HIV testing  
 History of previous TB 
 HIV infection  
 Presence of resistance to both RIF and INH (Multi-drug resistant TB) 
 Diabetes, malignancy, lung cancer, chronic bronchitis, sarcoidosis 
 Use of systemic steroids. 
The study included 336 patients of which 42 participants with pulmonary TB were 
selected as described below. Twelve patients relapsed within 24 months after initial 
cure and the remaining were matched to 30 cured patients. Each relapse patient was 
matched to two cured patients without relapse. The matching was done according to 
gender, extent of disease on chest X-ray (CXR) and where possible, duration of 
sample storage. Classification of CXR extent of disease was based on the criteria 
described by Simon, G 1971.111 Briefly, the presence and number of cavities as well 
as the overall extent of alveolar involvement (using the size of the right upper lobe or 
a whole lung as reference volumes) were used. The overall extent classified as either 
moderate or extensive in an adaption of the Simon method. 
 Relapse was defined as a second episode of TB with the same MTB strain as 
in the initial episode as determined by restriction fragment length 
polymorphism (RFLP) fingerprinting. The treatment outcome for episode one 
had to be ‘cure’ or ‘treatment complete’, as defined by WHO criteria112 
 A cured patient for the purposes of the present study did not develop a 
repeat episode of active TB during the two year follow-up period and had a 






The participants used for this study (Chapter 3) included only the 30 cured 
tuberculosis cases. These participants were longitudinally recruited from the study 
area and followed up for over 24 months. Blood samples were collected from every 
patient at each of the seven time points (from pre-treatment week 1, 2, 4, 6, 8 and 24 
months post-treatment) and stored at -80⁰C. Host markers using the Bio-plex 
platform were only evaluated on the whole blood culture samples that were only 
collected at diagnosis, week 1, week 2 and week 4. 
2.3.2 The evaluation of new host markers in Quantiferon supernatants 
(Micronutrient study) – Chapter 4 
This is a sub-study of a project entitled “The Effect of Vitamin A and Zinc 
supplementation on the Bacteriologic Response of persons with Pulmonary 
Tuberculosis in the Western Cape”. This was collaboration with Dr Marianne Visser 
from the University of the Western Cape (UWC) as the principle investigator. The aim 
of the main project was to evaluate the effect of vitamin A and zinc supplementation 
on the early (week eight) treatment response in adult, sputum smear positive TB 
patients. The findings of the main study were published by Visser et al., 2011113 
This study followed a community-based randomized double blind, placebo-controlled 
study design, where prospective patients were recruited and followed up at three 
separate time points, namely baseline, week 2 and 8. The recruitment of these 
participants was done between March 2005 and August 2008.   
All eligible patients presenting at Delft Clinic with newly diagnosed pulmonary 
tuberculosis were recruited in the study. The 154 patients that were recruited were 
randomly assigned to the micronutrient or placebo groups by the use of a random-
number generator using a block design, without stratification for HIV infection status. 
One study group of 77 participants received a single dose of 200 000 IU Vitamin A 
(retinyl palmitate) at study entry plus daily (five days per week) supplementation of 
15mg of zinc. The other group of 77 participants received the placebo (sunflower oil) 
supplement for two months. Both groups received standard anti-tuberculosis 









For the purpose of this study subjects were recruited based on the following criteria: 
Inclusion criteria 
 Aged 18-65 years 
 Two sputum samples testing positive for acid-fast bacilli by smear microscopy 
or one positive sputum specimen plus CXR findings suggestive of active TB 
as assessed by a pulmonologist experienced in the use of the Chest 
Radiograph Reading and Recording system.114 
 Willingness to undergo counselling and testing for HIV 
 
Exclusion criteria:  
 Previous treatment of TB disease 
 Known or suspected multi-drug resistance tuberculosis 
 Extra-pulmonary tuberculosis 
 Pregnancy  
 Birth six months prior to study entry  
 Liver disease, renal failure, congestive heart failure or neoplasm 
 Use of corticosteroids  
 The use of supplements containing Vitamin A, zinc or iron during the month 
preceding recruitment into the study. 
For the present study 19 pulmonary TB cases were randomly selected from the 77 
participants receiving the placebo supplement by using online randomization 
software (www.random.org). All of the participants’ samples were evaluated using the 
QFT IT. Host markers were evaluated on the additional aliquots of the QFT 
supernatants from the selected participants, from all time points (Diagnosis, week 2 
and week 8), using the Bio-plex platform as described below.  
2.4 Treatment Protocol 
All participants received the six-month DOTS anti-tuberculosis therapy which is 
recommended by the South Africa National Tuberculosis Programme. Briefly, the 
drug regimen consisted of a weight-related combination of INH, RIF, PZA and EMB 
during the first two months of therapy, followed by RIF and INH for the remaining four 
months. The intensive phase of treatment was prolonged to 3 months if sputum 





2.5 Laboratory Procedures 
2.5.1 Sputum and Culture Examination 
Sputum samples were cultured in liquid media using the BACTEC MGIT 960 system 
(Becton Dickinson, Sparks, MD). Direct sputum smear microscopy was performed 
using the ZN method with quantitative smear grading using the International Union 
against Tuberculosis and Lung Disease guidelines. Sputum samples and smears 
were processed at the National Health Laboratory Services (NHLS). 
2.5.2 QFT-IT 
QFT-IT is an assay that measures the cell mediated immune (CMI) responses 
against M.tb proteins. It is used as an in vitro diagnostic test for prior exposure to 
M.tb (primarily latent TB infection) and detects the release of IFN-γ by effector 
memory T lymphocytes when stimulated with M.tb specific antigens. 
2.5.2.1 Incubation and harvesting of blood 
Each sample of venous blood was aseptically collected into three vacutainer 1ml 
QFT-IT tubes (Nil, TB Antigen and Mitogen) that were supplied by the manufacturer 
(Cellestis, Victoria, Australia). The Nil tube contains saline and serves as a negative 
(background or unstimulated) control tube. The antigen tube contains the overlapping 
peptides representing the entire sequence of ESAT-6, CFP-10 and TB7.7 (Rv2584) 
and the mitogen tube contains phytohaemagglutinin (PHA) and is used as a positive 
control. After blood collection, each tube was shaken vigorously to ensure that the 
entire surface was coated with blood as recommended by the manufacturer.115 The 
tubes were then incubated at 37⁰C for 16-24 hours. After incubation, the tubes were 
centrifuged at 3000 x g for 15 minutes. Plasma (120µl) was harvested from all three 
tubes and aliquoted into 500µl tubes. The samples were then stored at -80⁰C until 
further analysis or until ELISAs were performed. 
2.5.2.2 QFT-IT ELISA procedure 
The QFT-IT ELISA was preformed according to the manufacture’s instructions.115 In 
short, the QFT-IT kit and samples were taken out one hour prior to the assay to 
ensure all samples and reagents reached room temperature. The ELISA plate was 
coated with the conjugate, samples and standands and left to incubate for two hours 
in the dark. This was followed by a washing step and enzyme substrate solution was 
added to all to wells and mixed on a plate shaker for two minutes. The plate was then 
incubated at room temperature in darkness for thirty minutes. Enzyme stopping 





each well was measured using a micro plate reader and read at 450nm and 650nm. 
These values were then analysed using QFT-IT analysis software from Cellestis 
version 2.50 to obtain results. 
 A positive result was determined if the TB specific antigen IFN-γ response 
(TB antigen – Nil) were ≥ 0.35 IU/ml regardless of the mitogen values.  
 A negative result was defined if the TB specific antigen IFN-γ response was 
≤ 0.35 IU/ml provided that the mitogen value was ≥ 0.5 IU/ml.  
 An indeterminate result was defined if the TB specific antigen IFN-γ 
response was < 0.35 IU/ml and the mitogen – nil response was < 0.5 IU/ml.  
2.5.3 Seven-Day whole blood assay 
Blood was collected into sodium heparin tubes (Becton Dickenson). Aliquots of the 
blood sample (1ml each) were transferred into two 50ml tissue culture flasks and 
diluted with 9ml of Roswell Park Memorial Institute medium (RPMI)-1640 (Gibco). 
After thawing at 37⁰C for at least two hours, a previously frozen aliquot of an isolate 
of M.tb (thawed from a frozen aliquot of H37Rv) was resuspended by gently shaking, 
and mixed by passing through a 1ml syringe. Both control and test cultures were 
prepared. The test whole blood cultures were inoculated with M.tb at 1 x 105cfu’s/ml 
in tissue culture flasks. One hundred and fifty micro litres 1 x 105 CFUs/ml were 
added to the test culture and 100µl of RPMI were added to the control culture. The 
cultures were incubated at 37⁰C and 5% CO2 for seven days after which both the 
supernatant and cell pellet were harvested. The supernatant (removed without 
disturbing the cell pellet), was filtered with a 5ml syringe, aliquoted and frozen at -
80⁰C until further analysis. The cell pellet was preserved for future analysis by adding 
10ml of Ribonucleic acid (RNA) stabilisation reagent (Roche) and frozen at -80⁰C.All 
steps in the whole blood assay were done in a bio safety level 3 laboratory. 
2.5.4 Principle of the Luminex Assay 
The technology makes use of 5.6µm polystyrene or magnetic microspheres which 
are internally colour-coded by two fluorescent dyes (a red and an infra-red dye) such 
that each microsphere set is unique and especially distinct from other sets. This 
allows for simultaneous quantitation of up to 100 analytes in a single assay well. 
Antibody specifically directed against the cytokine of interest is coupled to the colour-
coded polystyrene beads. The antibody coupled beads react with the sample 
(supernatant) containing the unknown concentration of the cytokine. After a series of 





a different epitope on the cytokine is added to the beads. This results in the formation 
of a sandwich of antibodies around the cytokine. The reaction mixture is detected by 
streptavadin-phycoerythrin (streptavadin-PE), which binds to the biotinylated 
detection antibodies. The well contents are drawn up into the Luminex suspension 
array system, which identifies and quantitates each specific reaction based on the 
bead colour and fluorescence.  
Biomarker levels were measured using the above mentioned kits according to the 
manufacturer’s instructions. All samples (QFT and 7-day WBA supernatants) were 
brought to room temperature, vortexed and spun down at 14000 rpm for two minutes 
to pellet any precipitate cellular debris. 
For the 3-plex cardiovascular disease/acute phase protein panel, a 1:8000 dilution of 
all the supernatants was performed in a two-step process: 5µl of the sample was 
added to 495µl of assay buffer and then mixed thoroughly (1:100 dilution) after which 
the sample was further diluted to 1:8000 by addition of 10µl of the 1/100 diluted 
sample to 790µl of assay buffer, followed by thorough mixing. 
For the 14, 13, and 27 plex assays, QFT supernatants were diluted 1 in 3 with the 
serum matrix diluent provided in the kits, while the 7-day WBA samples were tested 
neat. The dilution factors were decided after passed optimization experiments.116  
All the samples, standards and quality controls were assayed in duplicate. The levels 
of the host markers in the quality control reagents were all within the manufacture’s 
recommended expected ranges. The range of the standard curve for all the markers 
in the 27-plex assay was 3.2-10000 pg/ml. The standard curve of the high sensitivity 
assay was 0.13-2000 pg/ml and for the acute phase proteins SAA and SAP 0.08-250 
ng/ml and for CRP between 0.016-50.0 ng/ml.  
The soluble receptor assay had different standard curves for the various receptors as 










Table  2.1 The standard curves for the soluble receptors 
 
2.5.4.1 Evaluation of Supernatants by the Luminex multiplex 
immunoassay 
A total of 57 analytes were evaluated in the samples supernatants from the 
participants using Milliplex multiplex immunoassay kits (Millipore, St. Charles, 
Missouri, USA). The levels of all the analytes were evaluated in the unstimulated (Nil) 
and TB antigen QFT-GIT and live M.tb seven day whole blood stimulated and 
unstimulated supernatants. The detection of all the analytes were determined using 
four separate kits (pre-designated by the manufacturer), based on assay 
compatibility. These included a 14-plex soluble receptor panel kit, a 13-plex high 
sensitivity kit, a 3-plex acute phase proteins kit, and a 27-plex ‘normal sensitivity’ kit 



















1-7 12.2 – 50.000  
pg/ml        
24.4 – 100.000 
pg/ml          















27-plex kit 3-plex acute 
phase 
proteins kit 




● Epidermal Growth Factor 
(EGF) 
 ● Serum 
Amyloid protein 
A (SAP A) 
● soluble Epidermal 
Growth Factor 
Receptor (sEGFR) 
● IL-2 ● Eotaxin ● Serum 
Amyloid protein 
P (SAP P) 
● soluble Interleukin-
4 Receptor  
(sIL-4R) 




● soluble Tumour 
Necrosis Factor 
Receptor 1 (sTNFR1) 
● IL-5 ● FMS-like tyrosine kinase 3 
(FLT-3) 
 
● sgp130 ● IL-6 ● Fractalkine 
● soluble Interleukin 1  







● Granulocyte Colony 
Stimulating Factor (G-CSF) 
● sIL-6R ● IFN-γ ● GM-CSF 
● sTNFR2 ● TNF- alpha ● Growth Regulated 
Oncogene (GRO) 
● sIL-1R2 ● IL-7 ● Granulocyte Macrophage 
Stimulating Factor (GM-
CSF) 
● sIL-2Ralpha ● IL-8 ● Tumour Necrosis Factor-
beta (TNF-beta) 




● IL-10 ● IFN-alpha 
● soluble Vascular 
Endothelial Growth 
Factor Receptor 1 
(sVEGFR1) 
● IL-12p40 ● Interleukin 1 Receptor 
Antagonist (IL-1ra), IL-
1alpha, IL-3, IL-9, IL-12p40, 
IL-15, IL-17 
● VEGR2 ● IL-13 ● Vascular Endothelial 
Growth Factor (VEGF) 
  ●, Interferon inducible 
protein 10 (IP-10) 
● Monocyte Chemotactic 
protein 1 (MCP-1) 
 ●Macrophage Derived 
Chemokine (MDC) 
● Macrophage Inflammatory 
protein (MIP-1alpha) 
●Transforming Growth 








2.5.4.2 The Luminex assay procedure 
As recommended by the manufacturer, plates were pre-wetted with assay buffer and 
left at room temperature on a shaker (at 700 rpm) for 10 minutes. The assay buffer 
was then removed by vacuum aspiration. The standard and control reagents were 
then added to their respective wells, followed by the addition of assay diluent to the 
sample wells. The standards, controls, internal control and the supernatant solution 
were added to the appropriate wells, followed by the addition of antibody-coated 
fluorescent beads.  
After one hour incubation on a plate shaker at room temperature, the fluid was 
aspirated by the vacuum. The biotinylated secondary antibody was added, followed 
by streptavidin-labelled phycoerythrin antibody, with alternate washing and 
incubation steps between the additions of each antibody. Finally, the sheath fluid was 
added to each well and the beads were re-suspended by mixing the plate on the 
plate shaker, after which the plate was read on the Bio-rad Luminex reader. A 
standard curve was automatically generated by using the Bio-Plex Manager software 
version 4.1.1 (Bio-rad Laboratories) to determine the medium fluorescent intensities 
of the different analyte bead sets and respective concentrations. An illustration of this 































Figure 2.1 Principle of the Luminex technique  
Serum samples, controls, standards, 
assay diluent and antibody-coated 
fluorescent beadswere added 
Serum samples, standards, controls, assay 
diluent and antibody-coated fluorescent 
beads were added to the appropriate wells 
Plate was shaken for 1 hour at room 
temperature in the dark 
Biotinylated secondary antibody was added 
and incubated for 1 hour 
Streptavidin-labelled phycoerythrin antibody 
was added and incubated for 30 minutes 
Sheath fluid was added and read on 





2.6 Data and Statistical analysis 
All data was statistically analysed using Statistica version 9. All QFT analyte levels 
obtained from the Luminex assay were multiplied by 3 to correct for the dilution. All 
results were transformed using the logarithm for the base 10 to reduce variance in 
distributions. The unstimulated (nil) values have been subtracted from the antigen 
(Ag) stimulated values. A one-way repeated measure Analysis of Variance 
(ANOVAs) with least significant difference (LSD) post-hoc was conducted to compare 
time points. Values with a p ≤ 0.05 were considered significant.  
In an unbiased analysis approach, Qlucore Omics Explorer, Version 2.0 Beta 
(Qlucore AB, Lund Sweden) was used to construct heat maps. The clustering of the 
study participants was based on the host markers expression across the course of 
TB treatment. The colour assigned to a point on the heat map indicates how much of 
a particular host marker was expressed in a given participant sample. The 
expression level is generally indicated by red for high expression and green for low 
expression.131 
The Ingenuity Pathway Core analysis (IPA) (Redwood City California, USA) was 
used to interpret the host marker data according to biological processes, pathways 
and networks. Qlucore analysis identified significant host markers which expressed 
distinct patterns. The host markers in each pattern was defined as a value 
parameters for the IPA analysis. After the analysis, networks were generated by a 
score meaning significance. The Fisher exact test p value was used to determine the 
significance of the bio functions and pathways. Bio functions were grouped in 
disease and molecular functions. The pathway was generated by the ratio value 
which is the number of molecules in a given pathway that meet cut criteria, divided 














Feasibility assessment of biomarker discovery for 
early TB treatment response in live M.tb stimulated 
whole blood culture assays. 
3.1 Introduction 
The current treatment of TB consists of a six month regime divided into a four-drug 
intensive phase for two months, followed by a continuation phase of two drugs for 
four months.91 Since the discovery of rifampin in the 1960’s, no new drugs against TB 
have been introduced into clinical practice.38 The onset of MDR and XDR TB has 
created a demand for novel and effective treatments to reduce the burden of this 
disease. The WHO initiative DOTS is the most effective means of monitoring the 
treatment of tuberculosis.93 
The International Union against Tuberculosis and Lung Disease (IUATLD) has 
recommended that smear or culture status after two months of treatment, be used as 
a marker to evaluate early treatment response.117 However, the short coming of this 
procedure is that a diagnosis for unresponsive patients to therapy can only be made 
after two months. This enables the continual tissue damage107 and the possible 
development of drug resistance.118 In addition; this leads to lengthy trial periods in the 
evaluation of new drugs in clinical trials.105,107 Culture status at month two is a poor 
reference standard for measuring relapse or treatment failure.108 
 It has been suggested that if predicative biomarkers existed which reflected the 
efficacy of early treatment response it would allow patients to be stratified into 
relative risk groups according to treatment needs.98 This would allow the shortening 
of treatment in a majority of patients, who do not require the six month treatment 
regime. The strain on health care systems would also be alleviated as TB programs 
could focus on patients who do require the intensified drug regimen since these 
patients are at increased risk for poor treatment responses or relapse.97,107 The 
cohort sizes and costs in clinical trials would be reduced, due to the appropriate 
stratification of patients with similar risk profiles into treatment arms. These 






 A previous study conducted in our laboratory has identified several serum host 
markers including EGF, IL-10, IL-12p40, IL-13, MCP-1, MIP-1α, MIP-1β, IL-6, IP-10, 
TNF-α and sCD40 ligand which were shown to change during TB chemotherapy. 
Some of these markers could discriminate between patients that responded quickly 
to treatment and those with a slower response time as measured by week 8 sputum 
culture results.97 
The markers detectable in serum and plasma of patients may be non-specific for 
M.tb infection. This may be a result of the immune system being restricted in its array 
of responses against infectious diseases or other inflammatory disorders. This is 
evident in diseases such as diabetes, cardiac disease and several forms of cancer, 
where levels of acute phase proteins, chemokines and pro-inflammatory cytokines 
were shown to increase or decrease.119,120–123 
The identification of TB antigen specific markers might be more useful than the 
serum/plasma markers as antigen-specificity is a hallmark of the adaptive immune 
system and T cells, one of the central role players in this arm of the immune system, 
play such a crucial role in protection against TB.12 
The aim of this section of work was to evaluate if the stimulation of whole blood 
samples with live M.tb from TB patients undergoing treatment, results in the 
production of host markers which correlate with early treatment response as 















3.2 Study Design and Methods 
In this study, the sample population consisted of 30 TB participants, who were 
successfully treated without relapse (they were matched according to age, gender 
and CXR extent of disease to 12 participants who did develop relapse as part of 
another study). These participants were selected from a sample bank containing 336 
participants who were recruited as part of the Surrogate Marker study as mentioned 
in Chapter 2 (Figure 3.1). All these participants started anti-TB treatment at study 
entry, after the first sample collection. For this study a healthy control group was not 
available to compare cytokine levels against. 
 
 Whole blood samples were collected from all participants after which samples were 
cultured in the presence of live M.tb for 7 days as described in Chapter 2, (section 
2.5.3). Supernatants were harvested, aliquoted and frozen at -80⁰C after which the 
levels of 57 host markers were measured in the unstimulated and antigen-stimulated 
culture supernatants using the Luminex technology.  
 
Samples from four time points were available for analysis; at the onset of anti-TB 
treatment and 1, 2, 4 weeks thereafter (refer to chapter 2.3.1). No samples were 
collected after week 4 of treatment in this study. A one-way repeated measures 
ANOVA with LSD post-hoc was used in the analysis of the data. Statistical analysis 
of the immune response between groups (fast and slow responders) was performed 
using variance estimation, precision and comparative analysis including the LSD-test. 
The predicative power of the measured analytes for sputum culture status at week 8 
was assessed by general discriminant analysis (GDA). GDA were used to evaluate 
the predictive abilities of combinations of biomarkers for differentiating between fast 
and slow responders. Prediction accuracy were estimated using leave-one-out cross 
validation. This method was used due to the small sample size.   
The Qlucore software (Qlucore AB, Lund Sweden) was used to construct heat maps 
to generate patterns of changes in marker expression during treatment.113  
Ingenuity Pathway Core Analysis (IPA) (Redwood City California, USA) was used to 
identify signalling and metabolic pathways, molecular networks and biological 
processes that were affected by the host marker patterns observed.113   
For all analyses, the unstimulated, antigen-stimulated and M.tb specific marker levels 
(background subtracted from antigen stimulated levels) were used as separate 




























Figure 3.1 Flow diagram and summary of study design. 336 participants were initially 
recruited for the Surrogate Marker study. Forty two participants were selected for biomarker 
analysis: 12 TB relapses and 30 matched cured TB participants. The 30 participant’s culture 
supernatants were used in the present study for the identification of host markers of early 





























3.3.1 Clinical and microbiological markers of treatment response 
Of the 30 participants who were cured after 26 weeks of standard DOTS, 23 (76.7%) 
were male and 7 (23.3%) were female. They ranged between the ages of 19 to 64 
years. 
The clinical information collected on the participants is shown in Table 3.1 
Participants were classified into fast and slow responders to chemotherapy based on 
their culture status at week 8. The sputum M.tb culture and smear for acid fast bacilli 
results revealed that after 8 weeks of treatment 16 (53.3%) of participants were 
culture positive and 7(23.3%) were  smear positive. In 7 instances, sputum cultures 
were contaminated precluding their interpretation. 
 Smear results were not available for one participant at week 2 and for two 
participants at week 4. All of these participants were cured at month 6 (end of 
treatment).  
The whole blood cultures from the 16 slow responders (sputum culture-positive) and 
9 fast responders (sputum culture-negative) with available week 8 culture results 
were used for this section of work.  
The mean total time to positivity (TTP) increased over the eight weeks of treatment. 

















Table 3.1 Clinical characteristic of TB participants in this study 
 DX Week 1 Week 2 Week 4  Week8 
Culture  
    
Positive 30 (100) 30 (100) 27 (90)# 26 (86.7)# 16 (53.3)# 
TTP 3.5 ±1.81 
(1-7) 
8.63 ± 3.47 
(2-19) 
10.67 ± 4.94 
(3-27) 
12.83 ± 4.86 
(3-29) 
18 ± 4.22 
 
(13-29) 
Smear      
 Positive, n (%) 29 (96.7) 
 
 
26 (86.7) 22 (73.3)† 14(46.7)† 7(23.3) 
 
Definition of abbreviations: SD = Standard deviations, TTP = Total Time to Positivity 
Values are expressed as mean ± SD, range (min-max) 
# Week 2 and 4 had one contaminated culture and week 8 had five contaminated cultures    
†Week 2 has one missing smear result and week 4 has two missing smear results 







3.3.2 Response patterns observed in levels of host markers in 
participants with active tuberculosis at the onset of anti-TB treatment 
and 1, 2, 4 weeks thereafter 
Out the 57 host markers used in this study, G-CSF, IL-3, IL-9, IL-15, IL-17, MIP-
1alpha, IL-2, IL-13, sCD30, sIL-1R1, sRAGE, and sVEGFR3 were present at very 
low to undetectable concentrations in culture supernatants.  
Differences in levels of FLT-3 ligand, IL-1 alpha, GM-CSF, FGF-2,  MCP-1, IL-7, IL-5, 
IL-10, IL-2, TGF-alpha, MDC, MCP-3, IL-12p40, IL-12p70, MIP-1 beta, IFN-γ, 
sVEGFR1 and sVEGFR2 were detected between time points but not at significant 
levels (p ≤ 0.05). 
The levels of 27 markers showed significant changes during treatment and these 
followed 5 distinct patterns. The mean values of host markers and p values between 
the different times points are in Table 3.2 
(i) Host markers which showed a gradual decrease across all time points 
The unstimulated levels of chemokines and inflammatory cytokines i.e. TNF-beta 
(p<0.05), MCP-3 (p<0.01), Fractalkine (p<0.001) and sCD40 ligand (p<0.001) were 
higher at pre-treatment levels and dropped significantly during the four weeks of 
therapy (Figure 3.2). Ingenuity Pathways Analysis suggests that these markers play 
a pivotal role in the IL-17A signalling pathway (Figure 3.3).The primary function of 
these cytokines in this pathway is to support an inflammatory response to infectious 
disease by participating in antigen presentation, cell to cell signalling and interaction 
(Table 3.3).   
(ii) Host markers which showed a significant decrease by week 1 
The unstimulated levels of chemokines, acute phase proteins and inflammatory 
cytokines i.e. Eotaxin (p<0.01), GRO (p<0.05), IL-6 (p<0.001), IL-1ra (p<0.01), IP-10 
(p<0.001), IL-8 (p<0.001), TNF-α(p<0.05),  SAP P (p<0.05), sTNFR2 (p<0.001), SAP 
A (p<0.001), CRP (p<0.001),  IL-1β (p<0.05), sIL-2Ralpha (p<0.05), EGF (p<0.01) 
and the corrected stimulated levels (background corrected antigen stimulated levels) 
of IL-beta (p<0.05) and GRO (p<0.05) expressed high levels at  pre-treatment, 
dropped significantly by week 1 and remained at lower levels throughout the four 
weeks of treatment (Figure 3.4) These host markers play a role in the IL-17 and 





inflammation and function both in cellular movement and antigen presentation (Table 
3.4). 
(iii) Host markers which showed a significant increase at week 4 
The unstimulated levels of soluble receptors, pro and anti-inflammatory cytokines i.e. 
IL-4 (p<0.05), sEGFR (p<0.05), sIL-1R2 (p<0.001), sTNFR1 (p<0.05), and IFN-α 2 
(p<0.01) showed an increase between week 2 and week 4 of treatment (Figure 3.6). 
These markers are mainly involved in the inflammatory response to invading 
infectious pathogens by mediating communication between immune cells (Figure 
3.7). Their molecular and cellular functions include cellular development, 
maintenance and death (Table 3.5). 
(iv) Host markers which showed a transient increase at week 1 
Soluble cytokine receptors regulate inflammatory and immune events by functioning 
as agonists or antagonists of cytokine signalling.124 The unstimulated levels of the 
soluble receptors i.e. ssIL-6R (p<0.01, sIL-4R (p<0.01) and gp130 (p<0.05) (Figure 
3.8) had transiently elevated levels at week 1. Ingenuity pathway core analysis was 
only done for groups of four or more markers expressing the same pattern. 
(v) Markers which increased during treatment  
 VEGF (p<0.05) was the only marker which showed a low response at pre-treatment 














Table 3.2: Mean log transformed levels of cytokines in TB participants at the 
onset of anti-TB treatment and 1, 2, 4 weeks thereafter 
 
P values are for differences between time points on treatment versus baseline levels. 






Week 1 Week 2 Week 4 
TNF-betaNil 1.59 ± 0.14 1.50 ± 0.10* 1.28 ± 0.26*** 1.28 ±  0.14*** 
MCP-3Nil 1.82 ± 0.62 1.68 ± 0.48 1.50 ± 0.56** 1.46 ± 0.53** 
FractalkineNil 1.43 ± 0.41 1.40 ± 0.44 1.24 ± 0.47 1.17 ± 0.57* 
sCD40LNil 1.17 ± 0.48 1.10 ± 0.40 0.97 ± 0.48 0.73 ± 0.37** 
EotaxinNil 1.02 ± 0.32 0.91 ±0.36* 0.88 ± 0.32** 0.92 ± 0.35* 
GRONil 2.70 ± 0.47 2.48 ± 0.44** 2.36 ± 0.34** 2.41 ± 0.42** 
IL-6Nil 2.22 ± 0.46 1.91 ±  0.54** 1.91 ± 0.53** 1.97± 0.33 ** 
Il-1raNil 2.37 ± 0.39 2.08 ± 0.43** 1.93 ± 0.51** 2.12 ± 0.35 * 
IP-10Nil 2.54 ± 0.39 2.33 ± 0.52* 2.25 ± 0.47** 2.29 ±  0.46* 
IL-8Nil 2.40 ± 0.29 2.09 ±  0.34*** 2.15 ± 0.30 *** 2.08 ± 0.21 *** 
GROAg-Nil 2.43 ± 0.80 1.82 ± 1.04** 1.91 ± 0.99 ** 1.83 ± 1.05** 
TNF-alpha Nil 1.28 ± 0.42 1.02 ± 0.46** 1.07 ± 0.43** 1.06 ± 0.36** 
SAP PNil 3.74 ± 0.19 3.55 ± 0.19*** 3.73 ± 0.14 3.64 ± 0.20* 
sTNFR2Nil 3.05 ± 0.15 2.87 ±  0.17*** 2.86 ± 0.18 *** 2.85 ±  0.18*** 
SAP ANil 4.20 ± 0.65 3.46 ± 0.66 *** 3.35 ± 0.73 *** 3.30 ± 0.61 *** 
CRPNil 4.71 ± 0.30 4.19 ± 0.48 *** 4.21 ± 0.43*** 4.09 ± 0.52*** 
IL-betaAg-Nil 0.88 ± 0.49 0.55 ± 0.40** 0.57 ± 0.49** 0.73 ± 0.49 
IL-betaNil 0.89 ± 0.46 0.62 ± 0.53** 0.64 ± 0.41 ** 0.73 ± 0.45 
sIL-2Ralpha Nil 1.98 ± 0.30 1.87 ± 0.27 ** 1.83 ± 0.34 ** 1.92 ± 0.36 
EGF Nil 1.19 ± 0.57 1.16 ± 0.41 0.92 ± 0.38** 0.97 ± 0.41** 
IL-4Nil 0.40 ± 0.10 0.42 ± 0.13 0.38 ± 0.14 0.45 ± 0.15* 
sEGFRNil 3.32 ± 0.27 3.37 ± 0.19 3.31± 0.19 3.41 ± 0.17** 
sIL-1R2Nil 2.22 ± 0.30 2.27 ± 0.28 2.22 ± 0.26 2.46 ± 0.35*** 
sTNFR1Nil 1.85 ± 0.40 1.82 ± 0.31 1.73 ± 0.30* 1.87 ± 0.35 
IFN-alpha 2Nil 1.20 ± 0.45 1.17 ± 0.37 1.11 ± 0.40 1.36 ± 0.30* 
sIL-6RNil 2.79 ± 0.19 2.87 ± 0.14 ** 2.81 ± 0.15 2.83 ± 0.14 
sIL-4RNil 1.42 ± 0.23 1.64 ± 0.19 *** 1.45 ± 0.19 1.46 ±  0.28 
sgp130Nil 3.89 ± 0.18 3.95 ± 0.20** 3.92 ± 0.20 3.88 ± 0.21 







Figure 3.2 Host markers showing a gradual decrease during the first 4 weeks of 
treatment: Markers were grouped according to response patterns (only markers with 
significant changes are shown). The heat map was created using mean log values for each 
time point using the Qlucore Explorer Software where red indicated high expression and 
green indicates low expression. The line graphs are representatives for the response pattern 
that are shown. The data was analysed by one-way, repeated measures ANOVA with LSD 
post-hoc test. Different letters on the line graphs indicate that they were significantly different 
from each other with a p value of ≤ 0.05. Values with the same letters are not statistically 
































































































Table 3.3 The Ingenuity Pathway Analysis software illustrates the disease, 
molecular function and the pathway for the set of host markers which 
expressed a gradual decrease across the time points 
 
Figure 3.3 Ingenuity network analyses for specific host markers with a gradual   
decrease during the 4 weeks of treatment: The main pathway that was identified in this 
network was the IL-17A pathway. The diagram shows interactions between measured and 
unmeasured, putative molecules in this pathway. Red indicates measured markers with 












during the first 



















Figure 3.4 Host Markers showing a significant decrease by week 1: Markers were 
grouped according to response patterns (only markers with significant changes are 
shown).The heat map was created using mean log values for each time point using the 
Qlucore Explorer Software where red indicates high expression and green indicates low 
expression. The line graphs are representatives for the response pattern that are shown. The 
data was analysed one-way, repeated measures ANOVA with LSD post-hoc test. Different 
letters on the line graphs indicate that they were significantly different from each other with a 
p value of ≤ 0.05. Values with the same letters are not statistically different from each other. 
  


























































































































Table 3.4 The Ingenuity Pathway analysis software illustrates the disease, 
molecular function and the pathway for the set of host markers which 

















Figure 3.5 Ingenuity network analyses for specific host markers which show a 
significant decrease at week 1 of treatment: The main pathway that was identified in this 
network was the IL-17 and the acute phase response signalling pathway. The diagram shows 
interactions between measured and unmeasured, putative molecules in this pathway. Red 

























 IL-17 A signalling 
Pathway 










Figure 3.6 Host Markers showing a significant increase at week 4: Markers were grouped 
according to response patterns (only markers with significant changes are shown).The heat 
map was created using mean log values for each time point using the Qlucore Explorer 
Software where red indicates high expression and green indicates low expression. The line 
graphs are representatives for the response pattern that are shown. The data was analysed 
by one-way, repeated measures ANOVA with LSD post-hoc test.  Different letters on the line 
graphs indicate that they were significantly different from each other with a p value of ≤ 0.05. 
Values with the same letters are not statistically different from each other. 
  

























































































































Table 3.5 The Ingenuity Pathway analysis software illustrates the disease, 
molecular function and the pathway for the set of host markers which 
expressed a significant increase at week 4 
 
Figure 3.7 Ingenuity network analyses for specific host markers which show a 
significant increase at week 4 of treatment: The role that these host markers play is 
mediating communication between immune cells. The diagram shows interactions between 
measured and unmeasured, putative molecules in this pathway. Red indicates measured 
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Figure 3.8 Host Markers showing transient increase at week 1: Markers were grouped 
according to response patterns (only markers with significant changes are shown).The heat 
map was created using mean log values for each time point using the Qlucore Explorer 
Software where red indicates high expression and green indicates low expression. The line 
graphs are representatives for the response pattern that are shown. The data was analysed 
by one-way, repeated measures ANOVA with LSD post-hoc test.  Different letters on the line 
graphs indicate that they were significantly different from each other with a p value of ≤ 0.05. 
































































































Figure 3.9 The unstimulated levels of VEGF detected in patients with active TB on 
treatment. The data was analysed with one-way, repeated measures ANOVA with LSD post-
hoc test.  Different letters on the line graphs indicate that they were significantly different from 
each other with a p value of ≤ 0.05. Values with the same letters are not statistically different 






































3.3.3 Cytokine profiles in fast and slow responders to TB treatment 
The repeated measures analysis showed no significant differences in cytokine 
production by fast and slow responders during anti-TB treatment.  
Further analyses of the  data using GDA investigated multi-variable models (with a 
maximum of 4 variables) with the ability to classify fast and slow responders (month 2 
sputum culture results) at the  onset of anti-TB treatment and 1, 2, 4 weeks as 
measurements 
 The most frequently incorporated markers into the top 20 four-variable models were 
identified. The host marker sgp130Nil was the most frequently occurring diagnosis 
marker that discriminated between fast and slow responders (Figure 3.10). The 
combination of IFN-alpha 2Nil, sgp130Nil, sgp130Ag-Nil, sIL-4RNil was the top performing 
models. It classified fast responders with an accuracy of 88.9% and slow responders 
with an accuracy of 93.8% and in a resubstitution classification matrix with 88.9% 
and 87.5% respectively after leave-one-out cross validation.  
CRPAg-Nil was the most frequently occurring week 1 marker which could discriminate 
fast and slow responders (Figure 3.11). The combinations of week 1 levels of IL-
12p40Nil, CRPAg-Nil, IL-12p70Ag-Nil and sVEGFR1Ag-Nil classified fast and slow 
responders with an accuracy of 100% and 93.7%  respectively in a resubstitution 
classification matrix and with 88.9% and 87.5% respectively after leave-one-out cross 
validation.  
The host marker sgp130Nil was the most frequently occurring week 2 marker which 
could discriminate fast and slow responders (Figure 3.12). The combinations of week 
2 SAP AAg-Nil, IL-12p70Nil, sgp130Nil and sTNFR1Ag-Nil classified fast and slow 
responders with an accuracy of 100% and 93.7% respectively in a resubstitution 
classification matrix and with 90% and 87.5% respectively after leave-one-out cross 
validation.  
SAP ANil was the most frequently occurring week 4 markers which could discriminate 
fast and slow responders (Figure 3.13). The combinations of week 4 IFN alpha 2Nil, 
MCP-1Ag-Nil, MCP-3Ag-Nil and sVEGFR3Nil classified fast and slow responders with an 
accuracy of 100% and 70% respectively in a resubstitution classification matrix and 








Figure 3.10 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at pre-treatment. The columns represent the number of 










































































































































































































































Figure 3.11 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at week 1. The columns represent the number of inclusions of 









































































































































































































































Figure 3.12 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at week 2. The columns represent the number of inclusions of 












































































































































































































Figure 3.13 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at week 4. The columns represent the number of inclusions of 
























































































































































































Previous studies have reported that levels of several host markers in plasma/serum 
are affected by various inflammatory disorders and diseases. In this study we 
screened the profiles of 57 host markers in unstimulated and antigen (live M.tb) 
stimulated whole blood culture supernatants before and during the first 4 weeks of 
anti-tuberculosis treatment in participants with active TB, to determine if this long-
term antigen stimulated sample is suitable for discovery of biomarkers for early 
treatment response. All active participants used for the purpose of this study showed 
a positive response to treatment resulting in complete clinical remission. The markers 
that show significant changes during treatment would subsequently be candidates for 
further evaluation in TB treatment response studies. 
The results of this study reveal that during the early phase of treatment, multiple 
markers monitored in unstimulated participant samples became altered in their 
response. Conversely, in stimulated participant samples there was no effect seen in 
the response to the majority of these markers. Chemokine GRO and pro-
inflammatory IL-1beta were the only markers that showed changes in antigen 
stimulated responses (with unstimulated values subtracted).  
We also demonstrated that the host markers expressed different response patterns 
during early treatment. These included gradual decreases, decreases by week 1, 
increases at week 4, transient increases at week 1 or an ongoing increase during the 
four weeks of treatment. We used Ingenuity Pathway Analysis to explain the 
response patterns in a biological context. 
The chemokines (MCP-3, Fractalkine) and the inflammatory cytokine TNF-beta and 
sCD40 ligand levels showed a gradual decrease over the four weeks of treatment. 
The acute phase proteins (CRP, SAP P, SAP A, IL-6), pro and anti-inflammatory 
cytokines (TNF-α, IL-1beta, IL-1ra, sIL-2alpha, sTNFR1) and the chemokines (IL-8, 
IP-10, Eotaxin, GRO) were highly abundant before the initiation of treatment and 
significantly decreased in the first week of treatment. The response of both 
cytokine/chemokine groups decreased during the first four weeks of treatment 
possibly do so due to the therapy-induced reduction of the bacterial load.125 The 
decrease in antigen presentation maybe associated with decreased bacterial load, 
which in turn reduces cell to cell signalling which leads to a reduction of pro-





The anti-inflammatory cytokine IFN-α2, the Th1 suppressive cytokine IL-4 and the 
soluble receptor (sTNFR1, sEGFR and sIL-1R2) levels increase by week 4. As 
bacterial numbers decline, the immune system may attempt to restore homeostasis 
by inhibiting the function of pro-inflammatory cytokines like TNF and IL-1 by secreting 
soluble receptors. IL-4 now inhibits the Th1 response, preventing 
immunopathology.38 Other soluble receptors (sIL-4R, sIL-6R, sgp130) showed 
transient increases at week 1 and may also be a reflection of a transient need to 
inhibit the pro-inflammatory processes that marked the stage of uncontrolled bacterial 
replication. Once those inflammatory reactions are regulated, the levels of the soluble 
receptors return to baseline.  
 
VEGF was the only host marker that increased during treatment. VEGF is produced 
by macrophages and is a major mediator of angiogenesis and vascular 
permeability.126–129 Its unclear what the role of VEGF plays in the pathogenesis of TB 
but past studies have revealed that VEGF may play a role in the neovascularisation 
in granulomatous tissue which causes chronic inflammation associated with 
pulmonary damage.130 Some previous studies have shown elevated levels of VEGF 
in plasma of active TB patients and a decrease during TB treatment. 131,132 However, 
our study found an increase in VEGF during early TB therapy and is in keeping with 
another study which revealed that high serum levels of VEGF may be associated 
with the process of healing which requires the formation of new blood vessels to 
assist in tissue regeneration.133 Furthermore, here we measured cytokine levels in 7-
day culture supernatants and not in ex vivo samples like serum. For this reason, it is 
possible that levels of individual cytokines will be differentially affected by 
degradation of some cytokines, uptake by receptors or even continued production in 
culture. 
 
The marker, GRO and IL-1beta were 2 out of the 57 markers to produce a response 
in antigen stimulated cultures. 
 IL-1 beta is a pro-inflammatory cytokine with important functions in immunological 
control of infectious diseases like M.tb.134 IL-1 beta increases have been described in 
previous studies in those with active TB.135,136 Dlugovitzky D et al reported increased 
IL-1 beta production when peripheral blood mononuclear cells (PBMC) were 
stimulated with whole sonicated M.tb.137 In this present study the levels of IL-1 beta 
decreased with treatment. These results are similar to those of Tang and collegues138 
who showed that the levels of IL-beta were enhanced in pulmonary tuberculosis and 





GRO is a chemokine which is expressed by lung epithelium, fibroblasts, endothelial 
cells and alveolar macrophages. Several studies in vivo and in vitro suggest that 
GRO acts via the receptor CXCR2 and is an important mediator of neutrophil 
chemotaxis. GRO has been shown to be elevated in several inflammatory conditions 
and cancers.139-141 It has shown therapeutic potential in clinical trials of chronic 
obstructive pulmonary disease (COPD).142 GRO has not been identified as a host 
marker in tuberculosis but in this study we found decreasing levels during anti-
tuberculosis treatment, possibly reflecting a diminishing need for neutrophils as 
infection is gradually controlled. 
 
The comparison of fast and slow responders to treatment showed no significant 
difference between the two groups for any of the host markers. Additionally, the 
multi-variant analysis preformed on the onset of treatment and week 1, 2 and 4. 
Results showed that pre-treatment levels of sgp130Nil, IFN-alpha 2Nil, levels of CRPAg-
Nil, sVEGFR1 at week 1, levels of sgp130Nil, sTNFR1Ag-Nil at week 2 and levels of SAP 
ANil, EGF Ag-Nil at week 4 was able to predict week 8 sputum culture. 
 
The main limitation in our study is that a longer follow up period during treatment is 
needed in order to understand the effects of treatment on the levels of the different 
host markers that showed significant changes during treatment.  
 
3.5 Conclusion 
 In conclusion, antigen stimulated responses appear less promising than several 
markers in unstimulated cultures, which should rather be assessed ex vivo in serum 
or plasma. This would reduce the need for work in a BSL III facility, would reduce the 
risk to laboratory workers that working with live M.tb poses, would allow much more 
rapid results and would avoid the artefacts that are undoubtedly associated with 
unstimulated 7-day culture. Future evaluations of these markers in different 
outcomes of TB treatment, including relapse and failed treatment, need to be 
conducted. In addition, the change in response from baseline to the end of treatment 
should be determined as this may prove to be helpful when conducting M.tb 








The utility of Quantiferon-TB Gold In Tube (QFT- GIT) 
based short-term whole blood culture for the 
identification of M.tb-specific host markers for early 
treatment response 
 
    4.1 Introduction 
Whole blood assay can be used to measure antigen-specific T cell responses.143, 144 
This assay offers the advantage that many cytokines and therefore bio-signatures for 
different outcomes can be assessed. This may be of benefit in trials of new TB drugs 
or vaccines and may also provide insights into disease pathogenesis 145 In Chapter 3 
a whole blood assay using live M.tb was used and the majority of host markers 
showed early treatment changes in the unstimulated cultures with only two markers 
showing changes in antigen stimulated cultures. The whole blood assay in general 
has several advantages, as it requires a much smaller volume of sample compared 
to other assays and the T cells are maintained in an environment more similar to that 
found in vivo146 but the use of live M.tb imposes several disadvantages such as 
biohazard issues for laboratory workers and the 7-day lag time for results.146  
QFT-IT, one of the IGRA tests, offers several significant advantages over a 7-day, 
live M.tb stimulated whole blood assay. QFT-IT is a highly standardized diagnostic 
test for the diagnosis of latent M.tb infection. They are in vitro assays which measure 
sensitization to M.tb antigens by evaluating IFN-γ response in whole blood samples 
after overnight culture.147 The QFT-IT uses the ELISA to measure the amount of IFN-
γ released in response to M.tb specific antigens (ESAT-6, CFP-10 and TB 7.7).81 The 
IGRAs have been extensively studied and results have shown that they are as 
sensitive as, and more specific than the TST.148,149 There are many advantages of 
using the IGRAs rather than the TST for diagnosis of LTBI: they require a single 
patient visit and are not affected by prior BCG vaccination which decreases false-
positive responses, results can be obtained within 24 hours and small volumes of 
blood are required, which has been particularly useful when studying children.150,151 
The major limitation with this assay, as is the case for TST, is the inability to 





In previous studies it has been observed that IGRAs have limited clinical utility as a 
marker of treatment efficacy as the reports have been very inconsistent as many 
indicate an increase,147 decrease153,154 or no change155 in IFN-γ levels during 
treatment. IGRAs have also shown to have limited utility in a high burden HIV 
prevalent settings.153 
It also has been reported that the adaptation of the QFT-IT test can be used to 
discriminate between active and latent TB by screening multiple biomarkers other 
than IFN-γ in the culture supernatant.116,156–158 
The aim of this study was to evaluate if QFT -IT can be adapted to detect an array of 
host markers which could show early changes in treatment response and to 
determine if the changes in host markers during early treatment correlate with 
sputum culture conversion at week 8. 
The information that is acquired in this study will guide us to assess this sample type 











4.2 Study Design and Methods 
(i) Micronutrient Study 
In this study the sample population consisted of 19 TB participants who were all 
successfully cured at month 6. These participants were randomly selected from 77 
patients in the placebo arm of the Micronutrient study as described in Chapter 2 
(Figure 4.1). All these participants started anti-tuberculosis treatment at study entry 
after the first sample was collected. 
Briefly, 1ml of blood was drawn directly into the three QFT vacutainer tubes (Victoria, 
Australia). The tubes were incubated for 16-24 hours at 37⁰C and plasma was 
harvested and frozen in multiple aliquots at -80⁰C. The aliquot was used for the QFT 
IT ELISA and another set was used to measure the levels of 57 markers in 
unstimulated and antigen stimulated supernatants using the Luminex technology. 
For all analysis the unstimulated, antigen stimulated and M.tb specific marker levels 
(background subtracted from antigen stimulated levels) were used as separate 
variables during data analysis in order to access the changes in baseline 
unstimulated levels. 
(ii) Controls 
To compare the levels of the markers in TB participants we used historical data from 
healthy community controls (non-TB diseased participants). Levels of IL-2, IL-1ra, IL-
4, IL-5, EGF, IL-6, IL-7, TGF-alpha, IL-8, IL-12p70,IL-13, IL-15, IFN-γ, TNF-α, MCP-
1, sCD40L, MIP-1α, MIP-1 beta, IL-1α, GM-CSF,G-CSF,VEGF, IP-10, SAP P, CRP 
and SAP A were available from 34 community controls from another biomarker study. 
These results have been published by Chegou et al., 2009.135 Pair-wise comparisons 
of healthy control levels with each of the three participant time points (diagnosis, 
week 2 and week 8) was done with one-way ANOVA.  
Samples from the three on-treatment time points were compared using one-way, 
repeated measures ANOVA with LSD post-hoc test (refer to chapter 2.3.2).The 
Qlucore and Ingenuity Pathway Core Analysis were also used to analyse this data 
set. Analysis of the immune response between fast and slow responders was 
performed using variance estimation, precision and comparative analysis including 
the LSD-test. The predicative power of the measured analytes for sputum culture 





Although the main aim of the study was to evaluate treatment response, comparison 
of levels before and during early treatment with levels in healthy controls was 
deemed necessary as our data set did not include measures after completed 
treatment and as we therefore could not deduce whether levels could be anticipated 
to change further at later time points in therapy or after completion of therapy. Due to 
the cost of these tests the analyte levels were not repeated in healthy controls for the 




























Figure 4.1 Flow diagram and summary of study design. 154 participants were initially 
recruited for the Micronutrient study. 77 participants received placebo and 77 were on 
micronutrient supplementation. Nineteen participants from the placebo group were randomly 
selected and their QFT-GIT supernatants were used in the present study for the identification 



































4.3.1 Clinical and Microbiological markers of treatment response 
Of the 19 participants who were cured after 26 weeks of standard DOTS, 11 (57.9%) 
were male and 8 (42.1%) were female. They ranged between the ages of 18 to 59 
years. 
The clinical characteristics of the study participants are demonstrated in Table 4.1 
The sputum M.tb culture results revealed that 18 (94.7%) were positive at baseline 
and 11 (57.9%) were still positive at week 8 of treatment. 
The sputum smear for acid fast bacilli results showed that 18 (94.7%) were positive 
at baseline and 9 (47.4%) were still positive at week 8 of treatment. Significant 
differences were observed in the smear positivity rates between week 2 and 8 
(p<0.01) and between diagnosis and week 8 (p <0.01). 
At baseline 14 (73.7%) and at week 8 of treatment 16 (84.2%) of the study 
participants were QFT-IT positive (using the manufactures cut-off values). There 
were no significant differences observed in the QFT-IT results across the time points. 
Although all the participants were cured at month 6 (end of treatment), 11 (57.9%) 
were still culture positive at week 8 and 9 (47.36%) were still smear positive. The 
culture status at week 8 was used to stratify patients into slow and fast treatment 
responders. Eleven slow responders and eight fast responders were identified. 
TTP could not be used as a continuous variable, as the NHLS which performed the 
cultures, did not inoculate the MGIT tubes with a consistent sputum volume. 
Stratification into treatment response groups was therefore based on the 
dichotomous variable MGIT positive or negative. 
Of the 34 community controls that were recruited in Chegou et al., 2009 study, 14 
(41%) were male and 20 (59%) were female. The mean age was 31.8 years; they 
ranged between the ages of 11 to 60 years. The mean TST reading was 22.8mm 
with a range of between 0.0-46.0mm. The percentage of QFT-IT positivity in these 






Table 4.1: Clinical characteristics of study participants 
 
The proportion of test positive participants at each time point was compared using 
the WINPEPI software (www.brixtonhealth.com/pepi4windows.html). P 1 represents 
the p value for comparison between diagnosis and Week 2, P 2 for comparison 
between Week 2 and Week 8 and P 3 between Diagnosis and Week 8. The 













 DX Week 2 Week 8 P 1 P 2 P 3 
Culture 

























































4.3.2 The comparison of community controls and TB participants at the 
onset of anti-TB treatment, week 2 and 8  
The levels of IL-2, IL-1ra, IL-4, IL-5, EGF, IL-6, IL-7, TGF-alpha, IL-8, IL-12p70,IL-13, 
IL-15, IFN-γ, TNF-α, MCP-1, sCD40L, MIP-1α, MIP-1 beta, G-CSF, VEGF, IP-10, 
GM-CSF, EGF, SAP P, CRP and SAP A of the community controls at baseline were 
compared with the levels of TB patients at diagnosis, week 2 and week 8 on anti-
tuberculosis treatment. 
(i) No significant difference between controls and TB participants 
The levels of pro and anti-inflammatory cytokines, chemokines, growth factors and 
acute phase proteins i.e. IL-2Nil, IL-2Ag-Nil, IL-4Nil, IL-5 Nil, IL-5 Ag-Nil, IL-6 Nil, IL-6Ag-Nil, IL-7 
Nil, IL-7 Ag-Nil, IL-13 Nil, IL-15 Nil, IL-15 Ag-Nil, IFN-γ Nil, IFN-γ Ag-Nil, IL-12p70Nil, GM-CSFNil, 
TNF-αAg-Nil, TGF-α Ag-Nil, MCP-1Ag-Nil, sCD40L Ag-Nil, MIP-1 beta Ag-Nil, G-CSF Ag-Nil, VEGF 
Ag-Nil, GM-CSF Nil, GM-CSF Ag-Nil,  SAP P Ag-Nil, SAP A Nil and CRP Nil,   showed no 
significant differences between the community controls and TB patients at anytime 
point (not shown). 
 (ii) Significant baseline differences between controls and patients only at 
baseline (normalization of levels by week 2 of treatment) 
The levels of Th2 cytokines, IL-4Ag-Nil and IL-13Ag-Nil, a chemokine, MIP-1αAg-Nil, and 
two acute phase proteins, CRPAg-Nil and SAP A Ag-Nil  showed a significant difference at 
baseline when compared with controls (Figure 4.2) 
(iii) Significant baseline and week 2 differences between controls and patients 
with no significant differences at week 8 (normalization of levels by week 8 of 
treatment) 
The levels of anti-inflammatory cytokines, growth factors and acute phase proteins 
i.e. IL-1raAg-Nil, IL-1alphaAg-Nil, VEGFAg-Nil and SAP PNil respectively showed significant 









(v) Significant differences across all time points when compared to controls 
(no normalization of levels during observation period) 
The levels of growth factors, chemokines, pro-inflammatory, anti-inflammatory and 
acute phase proteins i.e. EGFNil, EGFAg-Nil, G-CSFNil, IP-10Nil, IP-10Ag-Nil,IL-8Nil,IL-8Ag-
Nil,MCP-1Nil, sCD40LNil, MIP-1αNil, MIP-1 betaNil, IL-6Nil, IL-12p70Ag-Nil, IL-15Nil, TNF-
αNil, TGF-αNil IL-1 alphaNil, CRPNil and sCD40LNil were significantly different at all time 
points (baseline, week 2 and week 8) in TB patients when compared to controls 








Figure 4.2 Mean concentrations of host markers in the Quantiferon supernatants that 
show significant differences at diagnosis between controls and TB patients. The 
vertical bars denote 95% confidence levels. The significant p values are shown for significant 
differences between the control group and the TB patients at the different time points: * 
p<0.05, **p<0.01. Pair-wise comparisons of healthy control levels with each of the three 
participant time points (diagnosis, week 2 and week 8) was done with one-way ANOVA. 
  














































































































Figure 4.3 Mean concentrations of host markers in the Quantiferon supernatants that 
show significant differences at diagnosis and/or week 2 between controls and TB 
patients. The vertical bars denote 95% confidence levels. The significant p values are shown 
for significant differences between the control group and the TB patients at the different time 
points: * p<0.05, **p<0.01. Pair-wise comparisons of healthy control levels with each of the 
three participant time points (diagnosis, week 2 and week 8) was done with one-way ANOVA. 
 






















































































Figure 4.4 (A) Unstimulated mean concentrations of host markers in the Quantiferon 
supernatants that show significant differences across all time points when compared 
to controls. The vertical bars denote 95% confidence levels. The significant p values are 
shown for significant differences between the control group and the TB patients at the 
different time points: * p<0.05, **p<0.01. Pair-wise comparisons of healthy control levels with 
each of the three participant time points (diagnosis, week 2 and week 8) was done with one-
way ANOVA. 
 
































































































































































Figure 4.4 (B) Unstimulated mean concentrations of host markers in the Quantiferon 
supernatants that show significant differences across all time points when compared 
to controls. The vertical bars denote 95% confidence levels. The significant p values are 
shown for significant differences between the control group and the TB patients at the 
different time points: * p<0.05, **p<0.01. Pair-wise comparisons of healthy control levels with 
each of the three participant time points (diagnosis, week 2 and week 8) was done with one-
way ANOVA. 
 


































































































Figure 4.4 (C) Antigen stimulated (background subtracted from antigen stimulated 
levels) mean concentrations of host markers in the Quantiferon supernatants that 
show significant differences across all time points when compared to controls. The 
vertical bars denote 95% confidence levels. The significant p values are shown for significant 
differences between the control group and the TB patients at the different time points:   
*p<0.05, **p<0.01. Pair-wise comparisons of healthy control levels with each of the three 
























































































4.3.3 Response patterns observed in levels of host markers in 
participants with active tuberculosis at the onset of anti-TB treatment, 
week 2 and 8 
The levels of 57 host markers were investigated in 19 study subjects with 
tuberculosis. The host markers that were investigated consisted of 
chemokines/cytokines, growth factors, soluble receptors and acute phase proteins.  
Out of the 57 markers that were used in this study, FLT-3 ligand, GM-CSF, IL-1 
alpha, IL-3, IL-9, IL-15, IL-17, IL-5, IL-12p70, sCD30, sEGFR, sgp130, sIL-1R1, sIL-
1R2, sVEGFR2 were present at very low to undetectable concentrations.  
Eotaxin, FGF-2, G-CSF, IL-12p40, MCP-1, MCP-3, MIP-1alpha, IL-1 beta, IL-10, 
TGF-α, IL-13, IL-7, IFN-γ, TNF-α, sIL-2Ralpha, sIL-4R, sIL-6R, sRAGE, sTNFR1, 
sTNFR2, VEGFR1 and VEGFR2 were present at detectable concentrations but there 
were no significant differences between the different time points. 
The levels of 17 markers changed during the course of treatment. These markers 
could be organised into four categories as shown below. Mean log transformed 
values for the different time points are represented in Table 4.2. 
(i) Host markers with a gradual decrease during the first 8 weeks of treatment 
The unstimulated levels of chemokines, acute phase proteins and growth factors i.e. 
SAP P (p=0.01), EGF (p=0.03), SAP A (p<0.001), CRP (p<0.001), IP-10 (p<0.001), 
sCD40L (p<0.001) and MDC Ag-Nil (p=0.07) were highest at pre-treatment levels and 
dropped significantly during treatment (Figure 4.5 A). According to Ingenuity Pathway 
Analysis these host markers are involved in the inflammatory response to infectious 
diseases mediating acute phase response signalling. These markers also play a role 
in cell to cell signalling and interaction, antigen presentation, cellular function, cellular 
maintenance and movement (Figure 4.6). 
(ii) Host marker with a transient decrease at week 2 
The unstimulated levels of chemokines and anti-inflammatory cytokines i.e. 
fractalkine (p=0.01), IFN-alpha 2 (p=0.03), IL-7 (p<0.001), IL-4 (p<0.001) and IL-4Ag-
Nil (p<0.05) had transiently decreased levels at week 2 (Figure 4.5 B). These markers 
are involved in inflammation and mediation of communication between immune cells. 
The molecular and cellular functions include cellular movement, cell to cell signalling 





(iii) Host markers with a transient increase at week 2 
These markers included the unstimulated levels of chemokines and inflammatory 
cytokines i.e. MIP-1 beta (p=0.07), MDC (p<0.001), GRO (p=0.03) and TNF-beta 
(p<0.001) (Figures 4.5 C).These markers are involved in inflammation and mediate 
differential regulation of cytokine production in macrophages and T helper cells by IL-
17 A and IL-17 F. These markers’ main cellular and molecular functions include cell-
to-cell signalling and interaction, cellular movement and molecular transport (Figure 
4.8) 
(iv) Host markers with a significant decrease at week 8 
These markers included the unstimulated levels of IL-1ra (p<0.001) and VEGF 
(p<0.001) (Figure 4.9). Heat maps and Ingenuity Pathway core analysis were only 



















Table 4.2: Mean log transformed values of host markers in TB participants at 


















Values are expressed as mean ± standard error of the mean (SEM). The p values 
are shown are for differences between diagnosis and the different time points. * 
p<0.05, **p<0.01, ***p<0.001 
  
Cytokine Diagnosis  
 
Week 2  Week 8  
SAP P Nil 4.79 ± 0.15 4.71 ± 0.11 4.49 ± 0.54** 
EGF  Nil 2.13 ± 0.45 2.06 ± 0.32 1.92 ± 0.56* 
SAP A Nil 5.60 ± 0.75 4.78 ± 1.04** 3.74 ± 0.93*** 
CRP Nil 5.99 ± 0.32 5.46 ± 0.32** 4.82 ± 0.92*** 
IP-10 Nil 3.74 ± 0.46 3.52 ± 0.48** 3.38 ± 0.51*** 
sCD40L Nil 3.53 ± 0.25 3.29 ± 0.36 3.15 ± 0.30 
MDC Ag-Nil 0.86 ± 1.17 0.37 ± 0.79* 0.21 ± 0.55* 
Fractalkine Nil 2.23 ± 0.64 1.61 ± 1.09** 2.29 ± 0.69 
IFN-alpha 2 Nil 2.01 ± 1.34 1.29 ± 1.00* 2.15 ± 1.07 
IL-7 Nil 0.52 ± 0.36 0.17 ± 0.36*** 0.40 ± 0.27* 
IL-4 Nil 2.01 ± 1.13 0.80 ± 1.01*** 1.83 ± 0.88 
IL-4 Ag-Nil 1.31 ± 1.03 0.53 ± 0.76* 1.02 ± 1.08 
MIP-1beta Nil 3.21 ± 0.45 3.42 ± 0.35* 3.31± 0.38 
MDC Nil 2.96 ± 0.21 3.15 ± 0.20*** 3.06 ± 0.19** 
GRO Nil 3.55 ± 1.07 4.10 ± 0.25* 4.00 ± 0.22 
TNF-beta Nil 1.63 ± 0.30 2.27 ± 0.62*** 1.74 ± 0.32 
IL-1ra Nil 2.26 ± 0.73 2.41 ± 0.58 0 ± 0*** 

























Figure 4.5 The Quantiferon host marker expression patterns during TB treatment: The 
Quantiferon supernatant cytokine levels were determined pre-treatment (Dx) and at week 2 and 8 of 
treatment in 19 active tuberculosis patients. Markers were grouped according to response patterns (only 
markers with significant changes during treatment are shown: (A) Host markers showing a gradual 
decrease during the first 8 weeks of treatment. (B) Host markers showing a transient increase at week 
2. (C) Host markers showing a transient decrease at week 2.The heat map was created using mean log 
values for each time point using the Qlucore Explorer Software where red indicates high expression and 
green indicates low expression. The line graphs are for one representative marker of the response 
patterns. Different letters on the line graphs indicate that they are significantly different from each other 













































































































































Figure 4.6 Ingenuity network analysis for host markers with a continuous decrease 
during the 8 week observation period. These host markers mediate acute phase response 
signalling.  The diagram shows interactions between measured and unmeasured, putative 









Figure 4.7 Ingenuity network analysis for host markers with a transient decrease at 
week 2: The role that these markers play is to mediate communication between immune 
cells. The diagram shows interactions between measured and unmeasured, putative 







Figure 4.8 Ingenuity network for host markers with transient increases at week 2: These 
markers mediate differential regulation of cytokine production in macrophages and T helper 
cells by IL-17A and IL-17F.The diagram shows interactions between measured and 
unmeasured, putative molecules in the pathway. Red indicated measured markers with 



























Figure 4.9 Mean levels of cytokines in QFT-GIT supernatants from TB patients at 
Diagnosis, Week 2 and Week 8 of treatment that respond with a significant decrease at 
week 8 (A and B): This data was analysed by mixed model repeated measures ANOVA (L.S 
means, 95%  confidence interval (CI).Different letters on the line graphs indicate that they are 
significantly different from each other with the p value <0.05. 


















































4.3.4 Cytokine profiles in fast and slow responders to TB treatment 
The repeated-measures analysis showed significant differences in cytokine secretion 
by fast and slow responders in antigen stimulated supernatants (background 
subtracted from antigen stimulated levels) of IL-13 (p=0.02) and IL-1 beta (p=0.04). 
The LSD test, which allowed comparison between fast and slow responders at 
specific time points, revealed that there was a significant difference in the cytokine 
levels between these two groups. Analysis of pre-treatment levels showed that fast 
responders had significantly higher levels of IL-13 (p=0.04) when compared with slow 
responders (Figure 4.10). The analysis of pre-treatment levels demonstrated that 
slow responders had much higher levels of IL-1beta (p<0.01) when compared to fast 
responders. (Figure 4.11). 
We further analysed the data using GDA to identify multi-variable models ( with a 
maximum of 4 variables) with the ability to classify fast and slow responders (month 2 
sputum culture results) using pre-treatment, week 2 and week 8 measurements.  
The most frequently incorporated markers into the top 20 four-variable models were 
identified. The host marker IL-1betaAg-Nil was the most frequently occurring marker 
which could discriminate fast and slow responders at pre-treatment (Figure 4.12).The 
combinations of G-CSFAg-Nil, MIP-1betaAg-Nil, IL-1betaAg-Nil and sIL-4R Ag-Nil classified 
fast responders and slow responders with an accuracy of 100% in a resubstitution 
classification matrix and with 100 % after leave-one-out cross validation 
CRPNil and IL-1raNil were the most frequently occurring markers which could 
discriminate fast and slow responders at week 2 (Figure 4.13). The combinations of 
IL-1raNil, IL-9Nil, CRPNil and sTNFR1Ag-Nilclassified fast responders and slow 
responders with an accuracy of 100% in a resubstitution classification matrix and with 
100% after leave-one-out cross validation.  
FractalkineAg-Nil was the most frequently occurring marker which could discriminate 
fast and slow responders at week 8 (Figure 4.14). The combinations of FractalkineAg-
Nil, IP-10Ag-Nil, TNF-betaAg-Nil and CRPAg-Nil classified fast responders and slow 
responders with an accuracy of 100% in a resubstitution classification matrix and with 


















Figure 4.10 Mean levels of IL-13Ag-Nil in QFT-GIT supernatants in TB patients at 
diagnosis, week 2 and week 8 of treatment. The vertical bars denote 95% CI. Different 
letters on the line graphs indicate that they are significantly different from each other with the 
p value <0.05. 
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Figure 4.11 Mean levels of IL-1betaAg-Nil in QFT-GIT supernatants in TB patients at 
diagnosis, week 2 and week 8 of TB treatment. The vertical bars denote 95% CI. Different 
letters on the line graphs indicate that they are significantly different from each other with the 
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Figure 4.12 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at pre-treatment. The columns represent the number of 
























































































































































































































Figure 4.13 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at week 2.The columns represent the number of inclusions of 






















































































































































































































































Figure 4.14 Frequency of individual analytes in top models for discriminating between 
fast and slow responders at week 8.The columns represent the number of inclusions of 










































































































































































































































4.3.5 Comparison of antigen stimulated levels in short term QFT-IT 
assay with the 7-day whole blood assay. 
We investigated the responses in antigen specific samples during early treatment in 
the 7-day whole blood culture (chapter 3) and the QFT-IT assay (present chapter). 
IL-1 beta and GRO were the only host markers which showed early changes in the 
antigen stimulated samples in the 7-day whole blood assay and MDC and IL-4 
showed antigen specific changes in QFT-IT assay. These two assays were 
compared at the two common time points, diagnosis and week 2. GRO and MDC 
expressed higher mean levels in the 7-day whole blood assay compared to the QFT-
IT assay. The baseline level of GRO in the 7-day whole blood assay was significantly 
different from the baseline level in the QFT-IT (p<0.001). The baseline and week 2 
levels of MDC was significantly different (p<0.01 and p<0.001 respectively) (Figure 
4.15). 
IL-4 and IL-1 beta were expressed at higher mean levels in the QFT-IT assay when 
compared to the live 7-day whole blood assay. The baseline and week 2 levels of IL-
1 beta (p<0.05 and p<0.001 respectively) and IL-4 (p<0.001 and p<0.05 respectively) 
were significantly different at baseline and week 2 (Figure 4.15). 
Generally, Nil levels of cytokines were higher in QFT than in the 7-day assay (not 
shown) but as discussed before these cytokines may have to be measured in ex vivo 


















Figure 4.15 Comparison of the QFT-IT and whole blood assay at DX and week 2: QFT-IT 
produced higher mean levels of: IL-1beta and IL-4 when compared to the whole blood assay. 
The live 7 day whole blood assay produced higher lives of MDC and GRO when compared to 




































































































































Previous studies have adapted the use of QFT-IT and have identified multiple 
biomarkers which can differentiate between active and latent TB infection. 
 In this study we screened the profiles of 57 host markers in unstimulated and 
stimulated QFT-IT supernatants before and during the first eight weeks of treatment 
in participants with active TB to determine which host markers change significantly 
during early treatment and therefore could be potential candidates for treatment 
response biomarkers. A highly standardized assay like the QFT would have the 
advantage that it could be used in different clinical trial sites across the world with 
storage of assay supernatants for subsequent biomarker discovery. The markers that 
have shown significant changes during early treatment could be further evaluated in 
TB treatment response studies. 
The major finding of this work is that multiple biomarkers were detected and showed 
significant changes in the unstimulated supernatants during early treatment 
compared to the majority of antigen stimulated supernatants that did not change 
significantly. However, unstimulated marker levels should rather be measured in ex 
vivo samples like plasma or serum to avoid artefacts due to degradation of proteins 
or due to binding to soluble or cell-bound receptors. The only markers whose antigen 
stimulated levels (antigen minus nil) change during treatment were the chemokine 
MDC and the anti-inflammatory cytokine IL-4. We also demonstrated that the host 
markers change with different response patterns during early treatment. These 
responses include gradual decreases, transient decreases by week 2, transient 
increases by week 2 and a significant increase by week 8 during the eight weeks of 
treatment. 
Some cytokine levels in TB patients were statistically significantly different at different 
time points and between patients and controls whereas these response patterns 
were of uncertain biological significance. This may be due to the small number of 
participants or may be due to varying levels of inflammation during the early stages 
of treatment. Some cytokines showed no treatment response during the observation 
period and were not different from control values and are therefore unlikely to add 
benefit to treatment monitoring. Other markers show more promise for monitoring 
treatment response. The group of cytokines that are expressed at significantly lower 
or higher levels than in controls and that change by week two of treatment may be 
valuable early treatment response markers and warrant further investigation. The 





observation would in all likelihood return to baseline levels later during treatment and 
further studies should investigate whether such presumed late changes are indicative 
of achieving sterilizing cure. 
The levels of acute phase proteins (SAP P, CRP, and SAP A), chemokines (IP-10 
and MDC)and growth factors (EGF) and sCD40L (which is released by platelets and 
triggers the release of inflammatory mediators159 )decreased gradually over the eight 
weeks of treatment. The disease function associated with these markers is broadly 
defined as ‘inflammatory responses’ by the IPA. The cellular and molecular function 
associated with these markers includes, antigen presentation, general cellular 
functions, cell to cell signalling. The decrease in these functions may be related to 
the decline in the inflammatory response that is associated with the reduction in 
bacterial load due to therapy.160 As bacterial numbers decline the need for a highly 
active inflammatory response, antigen presentation and communication between 
cells decreases too. 
The levels of inflammatory cytokines (IFN-alpha 2, IL-4 and IL-7) and the chemokine 
(Fractalkine) are transiently decreased at week 2, which leads to a decrease in 
inflammation, cellular movement and cell to cell signalling. Transient changes are 
generally not considered to be direct treatment effects but in this case, it may indicate 
transient immune regulation. As bacterial numbers fall during the phase of rapid 
bacterial killing, the immune system responds by reprogramming its functions. 
However, as the battle against the infection is by no means won at this stage and as 
a significant healing process needs to take place these markers return to the high 
pre-treatment levels after the initial dramatic fall of pathogen numbers.  
Similarly, the transient increase of markers may also be due to the need to reset 
immune responses as discussed in the previous paragraph. The inflammatory 
cytokine (TNF-beta) and chemokines (MDC, MIP-1beta and GRO) transiently 
increase by week 2 and this could also be a reflection of an early recovery  of the 
immune response that takes place when antibiotic treatment alleviates immune 
suppression induced by overwhelming numbers of mycobacteria.12 
VEGF and IL-1ra showed a significant decrease by week 8. VEGF, an angiogenesis 
mediator produced by macrophages has been shown to participate in wound healing 
and repairing of tissue.97 Previous studies have shown elevated levels of VEGF in 
plasma of active TB patients and decreased during anti-tuberculosis treatment.97,161 
This was also observed in this study. IL-1RA is a natural antagonist of IL-1 produced 





pulmonary tuberculosis and levels decline during treatment.158,163 The levels of IL-1ra 
were shown to decrease in our study. 
The markers, MDC and IL-4 were 2 out of the 57 markers to produce a response in 
antigen stimulated cultures. MDC is a chemokine that attracts activated T cells and is 
produced by macrophages and DC within secondary lymphoid tissues.164 Arias M et 
al., 2007 reported increased MDC production when whole blood was stimulated with 
M.tb specific antigens.165 In this present study the levels of MDC decreased with 
treatment. 
The comparison of fast and slow responders to treatment showed that the levels of 
IL-13Ag-Nil were found to be significantly higher in fast responders at the baseline level 
when compared to slow responders. IL-13 is produced by TH2 cells and is a 
mediator in allergic inflammation and disease.166 The role of IL-13 in M.tb is not well 
defined. Harris et al., 2007 shows that IL-13 contributes to autophagy-mediated 
killing of M.tb in human and murine macrophages.167 In a study done by Siawaya et 
al. in 2009 high levels of IL-13 were reported in fast responders compared to slow 
responders which corresponds with our study.97 Concentrations of IL-1 betaAg-Nil 
showed significantly higher levels in slow responders very early during treatment; this 
could suggest that increased anti-inflammatory response that accompany more 
extensive disease or a lack of early response to chemotherapy may lead to a delay of 
sputum conversion in patients.168 
Multi-variant analysis was performed on markers measured at the onset of treatment 
and week 2 and 8. Pre-treatment levels of IL-1betaNil and sIl-4R Nil, levels of IL-1raNil, 
CRPNil at week 2 and levels of fractalkineNil and IP-10Nilat week 8 were able to predict 
week 8 sputum culture outcome with 100% accuracy but this result should be 
interpreted with caution due to the small number of study participants. 
 
Out of the 57 markers that were evaluated in both assays only four markers showed 
antigen stimulated responses, IL-1beta and GRO in the 7 day whole blood assay and 
MDC and IL-4 in the QFT-IT assay. We compared these two assays at the two 
common time points, diagnosis and week 2 and it displayed that QFT-IT expressed 
much higher mean levels of IL-1beta and IL-4 compared to the 7–day assay.  MDC 
and GRO expressed higher levels in the 7 day assay when compared to the QFT-IT 
assay. These differences could be contributed to these assays have different 





IT and the 7 day whole blood assay have shown not to be good replacements of 
serum and plasma for the discovery of host markers for early treatment. 
The main limitation in this study, apart from the small number of participants, is that a 
longer follow up period during treatment was not available to follow the changed in 
host marker levels during the important sterilizing phase of treatment. However, the 
early changes remain important for the rapid evaluation of treatment success and for 
the evaluation of new drugs. This study sheds new light on the potential of some host 
markers in this context. 
4.5 Conclusion 
In conclusion, our preliminary results suggest that only a few of the 57 investigated 
host markers change during the first 8 weeks of treatment in QFT-IT antigen 
stimulated whole blood supernatants. Antigen stimulated responses appear less 
promising than several markers in unstimulated cultures, which should be assessed 
ex vivo in serum or plasma. Further studies of these markers in different outcome of 
TB treatment need to be conducted. In addition, further changes between week 8 
and the end of treatment should be investigated as some markers did not reach 

















Summary and Conclusion 
The only accepted measure of early TB treatment response comes two months after 
the initiation of treatment at the end of the intensive phase of therapy. This long lag 
time before non-response to treatment is not recognized and allows ongoing tissue 
destruction, continued spread of organisms and even the potential development of 
new drug resistance in patients on suboptimal treatment regimens. Baseline 
measurements may allow stratification of patients into clinical trial arms with similar 
treatment needs. This would reduce the required size of clinical trial groups and 
thereby decrease the costs in clinical trials.  
The choice of QFT-IT supernatants as sample types for the discovery of new 
biomarkers was based on the fact that this is a highly standardized commercial test 
with validated M.tb antigens and incubation times. Any new markers that are 
discovered have the potential to be translated into clinical use by making use of the 
well-developed QFT system where only the measurement of the new target analytes 
needs to be developed appropriately. Such an assay may be much more practical 
than the 7-day live M.tb assay with its bio-hazard issues for laboratory staff and 
requirement for a BSL facility.  
This thesis evaluated the measurement of multiplex cytokine arrays in supernatants 
from two different M.tb antigen stimulated culture methods. Firstly a 7-day, live M.tb 
stimulated whole blood assay was evaluated and secondly the commercially 
available QFT-IT test tube system was assessed to investigate if the stimulation of 
M.tb antigens from TB patients undergoing TB treatment results in the production of 
host markers which can predict early treatment response. 
Neither of the whole blood assays resulted in convincing antigen specific treatment 
responses. Many biomarkers in the unstimulated supernatants, however, showed 
early changes with distinct response patterns. Unstimulated culture responses should 
rather be assessed in ex vivo samples like serum or plasma due to possible artefacts 
due to degradation or uptake by cells in the cultures.  
The comparison of host marker levels between controls (albeit historical data) and 
patients at the different time points in the QFT-IT assay showed that some markers 
levels did not recover to normal values during the observation period and these 
markers may need further evaluation in future studies. The group of cytokines that 





by week two of treatment may be valuable early treatment response markers and 
warrant further investigation. The markers which remain significantly different from 
control values during the 8 weeks of observation would in all likelihood return to 
baseline levels later during treatment and further studies should investigate whether 
such presumed late changes are indicative of achieving sterilizing cure. 
When looking at different responder groups (fast and slow responders according to 
week 8 culture status) the analytes in the live M.tb assay showed no statically 
significant differences. However in the QFT-IT assay IL-1betaAg-Nil and IL-13Ag-Nil 
showed significant differences between fast and slow responders at pre-treatment 
levels. In this respect antigen-specific cytokine production may well have the 
potential to differentiate between responder phenotypes and may warrant further 
investigation. The GDA analysis to predict week 8 culture status performed with 
accuracy between 70-100% but these results should be interpreted with caution due 
to the small number of participants in both studies. These markers would also have 
to be tested in different outcomes of TB treatment, including relapse and failed 
treatment.  
In conclusion, antigen-specific responses showed only limited potential for early TB 
treatment response monitoring but may have potential in differentiating between 
treatment outcomes. The QFT-IT samples do not appear to be equivalent to live M.tb 
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